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CHAPTER ONE 
INTRODUCTION 
According to the World Health Organization (WHO) each year 8.2 million people 
die worldwide from cancer (World Health Organization, 2016).  In the United States 
cancer is the second leading cause of death, and the American Cancer Society (ACS) 
estimates that one in two men and one in three women living in the U.S.  will develop 
cancer at some point in their lives (American Cancer Society, 2016). Due to the 
prevalence of cancer there are countless institutions and scientist researching cures, 
treatments, and other areas of aid. The ACS has invested over $4 billion in research since 
1946 (American Cancer Society, 2016). The National Cancer Institute, the U.S. 
government’s primary agency for cancer related research, funded 3,100 institutions and 
over 14,000 investigators in 2014 (National Cancer Institute, 2016). Their efforts have 
assisted in lowering the death rate of cancer by 22% from 1990-2011 (National Cancer 
Institute, 2016). Although annual death rates are consistently decreasing, the projected 
number of new cases of cancer will increase by 70% over the next 20 years.  
 There are several options available for the treatment and management of cancer, 
some of which are: chemotherapy, radiation therapy, surgery, angiogenesis inhibitor 
therapy, and photodynamic therapy. Chemotherapy is the most popular course of 
treatment. Chemotherapy uses drugs to stop or slow the growth of cancer cells. It is often 
combined with radiation therapy of surgery. A major drawback of chemotherapy is its 
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robustness. It attacks both cancerous and healthy cells which leads to many unwanted 
side effects. 
 Radiation therapy damages cancer cells’ DNA by using X-rays, gamma rays, or 
other charged particles. This method of treatment can damage healthy cells as well. 
Surgery is commonly coupled with radiation therapy to remove the tumor and some of 
the tissues around it, but there is high incidence of reoccurrence. 
 Angiogenesis inhibitor therapy prevents the formation of new blood vessels which 
in return prevents tumors from growing. This type of treatment does not “cure” the 
patient it only halts the tumors growth. To rid the patient of the cancer this therapy is 
combined with radiation and/or chemotherapy, leading to aforementioned unwanted side 
effects. 
Photodynamic therapy (PDT) use light for the treatment of cancer (Figure 1). A 
light sensitive drug is given to a patient and absorbed by cells throughout the body. After 
a period of time most of the drug leaves the body, but the cancer cells retain the drug. The 
cells laden with the drug is exposed to light and the drug becomes toxic to cells 
destroying the cancer. One limitation of this method is the light needed to activate most 
drugs cannot pass through more than one centimeter of tissue (Vrouenraets, et al., 2003) 
therefore this restricts the types and sizes of cancer treated. Also, the drug is absorbed by 
cells throughout the body and can be retained by non-cancerous cells which leads to 
unwanted cell death and prolonged light sensitivity throughout the entire body.   For 
these reasons, our research focuses on the development of new PDT agents to increase 
specificity and to widen the scope of its use.  
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Figure 1. Photodynamic Therapy Schematic. A photosensitizer is given to the patient 
either topically or intravenously. Cancerous tumors preferentially retain the 
photosensitizer while healthy cells do not. The tumor is then irradiated with light at the 
appropriate wavelength which in turns activates the photosensitizer to become cytotoxic 
to the tumor. (Mroz, et al., 2011)   
 
Historical Perspective on Photodynamic Therapy 
The use of phototherapy can be traced back to Ancient Egypt, Indian, and Chinese 
civilizations. In 1900 Oscar Raab observed that acridines (Table 1) in the presence of 
daylight are lethal to protozoan paramecium (Pervaiz and Malini, 2006). Raab along with 
his mentor, Herman Von Tappeiner, coined the term “photodynamic reaction” to 
differentiate their dynamic photobiological reactions that occurred in the presence of 
molecular oxygen from the photosensitization of photographic plates by certain 
chromophores (Pervaiz and Malini, 2006). In 1901 Niels Finsen discovered that red light 
can be used in the prevention of the formation and discharge of small pox pustules. He 
also discovered that ultraviolet light can be used to treat cutaneous tuberculosis (Dolman, 
et al., 2003). He was awarded him the Nobel Prize in 1903 for this research (Dolman, et 
al., 2003). In 1903 Tappeiner and Jodlbauer treated skin tumors with topically applied 
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eosin (Table 1) and white light (Dolman, et al., 2003). This was the beginning of modern 
PDT. 
Modern PDT began with the study of porphyrins as photosensitizers. In 1911 
Hausmann studied hematoporphyrins (Table 1) to determine their photosensitivity and 
phototoxic effects (Pervaiz and Malini, 2006). In 1955 hematoporphyrin derivatives 
(HPD) were developed by Samuel Schwartz (Pervaiz and Malini, 2006). These 
derivatives were more phototoxic than hematoporphyrins (Pervaiz and Malini, 2006). 
Five years later Richard Lipson and Edward Baldes at the Mayo Clinic showed that 
Schwartz’ HPD localized to tumors and emitted fluorescence which could be used to 
detect tumors (Pervaiz and Malini, 2006). Thomas Dougherty reported in 1975 that HPD 
and red light destroyed mammary tumor growth in mice and J.F. Kelly used HPD and 
light to kill bladder carcinoma in mice (Pervaiz and Malini, 2006). The first PDT drug 
was approved by the Federal Drug Administration (F.D.A.) in the U.S. in 1993.  
Acridine Eosin Hematoporphyrin 
 
 
 
 
 
 
 
 
Table 1. Early Photosensitizers: Acridine and Eosin were observed in 1900 and 1903 
respectively to be lethal in the presence of light. Hematoporphryins were used in 1911. 
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Photodynamic Therapy Mechanism 
PDT has three requirements: a photosensitizer (PS), light at an appropriate 
wavelength, and molecular oxygen. A PS is a molecule that upon activation by light at a 
particular wavelength in the presence of molecular oxygen produces reactive oxygen 
species (ROS). The PS absorbs photons from light and this energy promotes one electron 
from the singlet state to a high energy orbital but it retains its spin. This state is short 
lived and is relaxed by fluorescence or internal conversion to heat (Robertson, 2009). 
This excited state may also undergo intersystem crossing in which the spin of the excited 
electrons inverts and forms an excited triplet state. This triplet state is long lived and can 
proceed via two routes, Type I reactions and Type II reactions (Figure 2) (Robertson, 
2009). In Type I reactions the PS in the triplet state reacts directly with a substrate. The 
PS tranfers a proton and/or electron to the directly to the substrate to create a radical 
anion and/or cation respectively. These radicals then react with molecular oxygen to 
produce ROS (Robertson, 2009). In Type II reactions the PS in the excited triplet state 
reacts directly with molecular oxygen to produce singlet state oxygen (Robertson, 2009). 
Type I and II occur simultaneously and the ratio of the two is determined by the PS, 
concentration of substrate, availability of molecular oxygen, and various other factors.  
Hydroxyl radicals and singlet oxygen are both very reactive and have short half live 
(<0.04 µs), thus only molecules in close proximity to the ROS production site  (<0.02 
µm) are affected by PDT (Pervaiz and Malini, 2006). 
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Figure 2. Type I vs. Type II reaction pathway. The PS absorbs photons from light and 
this energy promotes one electron from the singlet state to a high energy excited orbital. 
This excited state may undergo intersystem crossing in which the spin of the excited 
electrons inverts and forms an excited triplet state. This triplet state can proceed via two 
routes, Type I and II reactions. (Cieplik, et al., 2014) 
 
Modern Photosensitizers 
 An ideal photosensitizer will be chemically pure, chemically and physically 
stable, have a short time span between administration and accumulation in tumors, 
exhibit high selectively for cancerous cells, be retained preferentially by the cancerous 
cells, have minimal dark cytotoxicity, be cytotoxic only upon photoactivation, have a 
high quantum yield for the production of singlet oxygen, and be excreted from the body 
quickly (Pervaiz and Malini, 2006; Dolmans, et al., 2003). Absorption between 600-800 
nm has been deemed the optimal therapeutic window (Figure 3). Absorption and 
scattering of light by tissue increase as the wavelength decreases (Ethirajan, et al., 
2011;Pandey and Zheng, 2000). Nucleic acids and amino acids are present in tissue and 
7 
 
they absorb light between 250- 300 nm. Therefore, if a PS has a maximum absorbance 
over 600 nm these components will have very little effect on the PS effectiveness. 
Hemoglobin is the main component of tissues and is the biggest contributor to its 
absorption spectrum. Hemoglobin’s absorptions peaks are all below 620 nm and those 
close to 620 nm are very weak. Melanin is also contained in tissues and has a broad 
absorption spectrum with strong absorption at shorter wavelengths (Ethirajan et al., 
2011,Franck and Nonn, 1995). Taking into account all of the components mentioned 
which absorb below 600 nm means that light penetration is minimal at wavelengths <600 
nm. Wavelengths above than 800 nm do not provide enough energy to form a sizeable 
yield of ROS upon photoactivation (Ethirajan et al., 2011; Agostinis et al., 2011). 
 
 
Figure 3. Optimal Therapeutic Window. Wavelength below 600nm are mainly absorbed 
by nucleic acids, amino acids, melanin, and hemoglobin. Wavelengths above 800 nm do 
not provide sufficient energy to generate appreciable amounts of singlet oxygen. 
(Ethirajan et al., 2011; Seery, 2016) 
 
First Generation Photosensitizers 
Hematoporphyrins and HPD are referred to as first generation PS (Bonnet, 1999). 
HPD have a strong absorption band at 400 nm, commonly called the Soret band, and a 
four band absorption, Q band, which appears at 500, 540, 570, and 630 nm (Bonnet, 
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1999).  Photofrin®, was the first porphyrin based PS used in clinical trials and 
subsequently the first to receive approval for use in the U.S. and Canada for the 
treatments of bladder, gastric, endobronchial, brain, and esophageal cancer (Dolman, et 
al., 2003). Photofrin® consists of about 60 different porphyrins (Orenstein, et al., 1996). 
Woodburn et al purified the porphyrins contained in Photofrin® and determined that 
porphyrins with cationic side chains localized in mitochondria and those with anionic 
side chains localized in lysosomes(Orenstein, et al., 1996; Woodburn, et al., 1991). 
Woodburn further investigated and determined that localization in mitochondria provided 
the most cellular death Orenstein, et al., 1996; Woodburn, et al., 1991;Woodburn, et al., 
1992).  
 These first generation PS were effective and made from readily available 
inexpensive reagents. Yet, HPD are complex mixtures that are difficult to reproduce, 
have modest activity, and poor selectively.  In addition, first generation PS like 
Photofrin®   have four to six week patient photosensitivity (Josefen and Boyle, 2008). 
Furthermore, the absorption at 630 nm, is very weak and outside of the optimum 
therapeutic window (Yamamto, et al., 1999, Hirth and Michelsen, 1999). The weak 
absorption is compensated by using high doses of light of and drug which increases 
harmful side effects (Bonnet, 1999; Jori, 1992). These drawbacks lead to the creation of 
second generation PS. Many of these PS are porphyrin derivatives due to porphyrin’s 
efficiency to generate singlet oxygen, lack of dark cytotoxicity, its ability to absorb light 
at longer wavelengths and have intense bands above 600 nm.  
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Second Generation Photosensitizers 
Porphyrins. In order to capitalize on the advancements of Photofrin®, second 
generation PS began with attempts to produce pure porphyrins (Figure 4a). Many 
substituted porphyrins that have the lowest energy band red-shifted and/or intensified 
were synthesized.  m-THPP (5,10,15,20-tetraakis(m-hydroxy-phenyl)porphyrin (Figure 
4b) was determined to be 25-30 times more potent than HPD. Sulfonated derivatives of 
tetraphenylporphyrins (TPP) (Figure 4c) were synthesized, yet they appear to have some 
neurotoxicity in rats (Bonnet, 1999).  
 
A 
 
B 
C 
 
Figure 4. Chemical Structure of Porphyrins. (a) Porphyrin (b) m-THPP (c) TPP 
Chlorins.  Chlorins (Figure 5A) have strong absorption bands in the red region 
(Bonnet, 1999). They are derived from chlorophyll. They differ from porphyrin by the 
absence of at least one double bond in one of the pyrrole rings in the chlorin. Visudyne®, 
a benzoporphyrin derivative (BPD) (Figure 5b) is a chlorin synthesized from 
protoporphyrin that has absorption at 690 nm and it is rapidly accumulated in tumors 
which allow for irradiation on the same day that it is injected (Detty, et al., 2006). 
Visudyne® has been approved for the treatment of wet age-related macular degeneration 
in the U.S. since 2000. It has a relatively short half-life with skin photosensitization 
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lasting less than a week. Foscan®, a synthetic chlorin, 5,10,15,20-tetraakis(m-hydroxy-
phenyl)chlorin (m-THPC) (Figure 5c) is a potent photosensitizer that was approved in 
2001 for use in Europe, Norway, and Iceland (Pervaiz and Malini, 2006). The U.S. Food 
and Drug Administration (FDA) rejected Foscan® in 2000 (Woodburn, et al., 1992). 
Foscan® has a strong absorption peak at 652 nm, and drug and light dose are ten times 
lower than HPD. Foscan® is also 25-30 times more effective than HPD, but it lacks 
selectively, and has a six week skin photosensitization period which is a major drawback.  
 
A 
 
B 
 
C 
 
Figure 5. Chemical structures of Chlorins. (a) Chlorin (b)BPD (c)Foscan (m-THPC) 
Phthalocyanines and related naphthalocyanines. Phthalocyanines (Figure 6b) 
and naphthalocyanines (Figure 6a) have macrocyclic π-system these compounds have 
strong absorption at 670 nm and 770 nm respectively. Due to their strong absorptions 
only a small dose is needed (Nyman and Hynninen, 2004; Bonnet, 1995). Phototoxicty 
increases when they are chelated with Zn3+ and Al3+. These metals extend the lifetime of 
the triplet state (Orenstein, et al., 1996). To increase hydrophilicity, sulfonated derivates 
were synthesized (Woodburn, et al., 1992). Photosens®, a sulfonated aluminum 
phthalocyanine (Figure 6c), has been successfully used in clinical studies for the 
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treatment of cutaneous and endobronchial lesions and head/neck tumors (Uspenskii, et 
al., 2000; Sokolov, et al., 1995). Cellular uptake and phototoxicity are directly 
proportional to the degree of sulfonation (Woodburn, et al., 1992). Unfortunately, 
sulfonation could not be controlled, and the product is a mixture of sulfonated 
phthalocyanines that could not be separated (Woodburn, et al., 1992).   
 
a 
 
b 
 
c 
 
Figure 6. Chemical Structures of Phthalocyanines and Naphthalocyanines.  
(a) naphthalocyanine (b)phyalocyanin (c) Photosens® (AlPcS4). 
 
d-Aminolevulinic acid (ALA). ALA (Figure 7a) is a naturally occurring amino 
acid, and an intermediate in the synthesis of heme.  During the biosynthesis of the heme 
ALA is converted into proporphyrin IX (PpIX), which is phototoxic. PpIX (Figure 7b) 
accumulates in tumor with slight selectivity due to the activity of two different enzymes, 
ferrochelatase and porphobilinogen deaminase. Ferrochelatase is responsible for 
incorporating iron into PpIX, and porphobilinogen deaminase is responsible for forming 
uroporphyrin from porphobiligen (Woodburn, et al., 1992).  This provides for higher 
selectivity than Photofrin® but the maximum absorption is at 635 nm. Also, ALA is 
hydrophilic which makes it difficult penetrate cell membranes (Woodburn, et al., 1992). 
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A 
 
b 
 
Figure 7. Chemical Structures of ALA and PpIX. (a)ALA (b)PpIX 
Although first and second generation photosensitizers are beneficial in the 
treatment of cancers, they have one major disadvantage. They are not tumor selective. 
These photosensitizers accumulate in both normal and cancer cells which causes severe 
side effects. Therefore, a third generation of photosensitizers is currently being 
investigated. This new generation of compounds will maintain or enhance the 
characteristics of second generation PS, yet offer enhanced tumor selectivity.  
Targeted PDT 
A major problem with current cancer therapies is the low selectivity of the anti-
cancer drug. Low selectivity of the drug allows for the toxic effects of the drug to exerted 
on both healthy and cancerous tissue. PDT can be considered to have increased 
selectivity over traditional cancer therapies because the toxic effects of the drug in only 
induced by light, and the tissues not exposed to light will be spared the toxic effects. Yet, 
some tissues that are exposed to environmental light after administering PS can exhibit 
some phototoxicity that persists for several weeks after treatment. Therefore, targeted 
PDT is the focus of the third generation PS. By covalently or non-covalently attaching a 
targeting moiety to the PS specificity is increased. Such approaches have included the use 
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of low density lipoproteins (LDL) conjugates, monoclonal antibodies conjugates, 
transferrin conjugates, and macrophage scavenger receptor mediated protein conjugates. 
Conjugates of PS to small molecules such as steroids, and sugars to nanoparticles have 
been investigated to improve cell-type specificity in targeted PDT. 
Liposomes and low density lipoproteins. Liposomes prepared with the ethoxy 
castor oil, Cremphor-EL, has been used for the delivery of hydrophobic PS (Reddi, 
1997). It was shown that 70-80% of hematoporphyrin that was administered in 
dipalmitoylphosphatidylcholine (DPPC) liposomes became associated with lipoproteins, 
while 10% of hematoporphyrin was associated with protein fraction after delivery in 
phosphate buffered saline (Reddi, 1997). These studied indicated that the liposomal 
hematoporphryin accumulated in the tumor at a slower rate than the free drug, but it 
reached a maximum tumor concentration twice as high. Importantly, the skin 
concentration was lower than the free drug (Reddi, 1997).  
 Proliferating tumor cells and tumor microvascular endothelial cells overexpress 
LDL receptors. Thus, LDL conjugates can be used as targeting vehicles to enhance a PS 
intracellular accumulation and potentially its photodynamic activity via receptor 
mediated endocytosis pathway (Sharman, et al., 2004). LDLs also play an important role 
in the transport of hydrophobic PS across the plasma membrane (Reddi, 1997). The 
binding of serum proteins to the PS is mainly controlled by the hydrophilicity of the PS 
(Reddi, 1997). Moderately hydrophobic PS have been shown to be transported in the 
bloodstream by albumin, whilst highly hydrophobic are transported by lipoproteins. In 
human erythrocytes, phthalocyanine-loaded LDL conjugates have been shown to induce 
14 
 
cytotoxic effects by targeting specific thiol groups at the cell membrane (Martins, et al., 
2002). The efficiency and selectivity of PS delivery to LDL receptors in cancer cells 
depends on the conformational change of the LDL structure. The hydrophobic Zn(III)-
phthalocyanine (ZnPc) PS bound to human LDL (ZnPc-LDL) exhibits low affinity for 
LDL receptors and the conjugate was internalized into human HT1080 fibroblasts 
through non-specific endocytosis. The lack of affinity was due to changes in the 
apolipoprotein-B structure induced by phthalocyanine association in the ZnPc-LDL 
conjugate (Polo, et al., 2002). To improve the incorporation of phthalocyanine-LDL 
complexes, an attempt has been made to introduce a 12 carbon alkyl chain to aluminum 
tetrasulfonated phthalocyanine (AlPcS4) through a sulfonamide bond (Urizzi, et al., 
2000). This conjugate showed tumor regression activity and was effective against A549 
adenocarcinoma lung cancer cells (Sharman, et al., 2004; Urizzi, et al., 2000). 
 To enhance selectivity PS-LDL conjugates have been coupled to other targeting 
moieties such as folate (Zheng, et al. 2005; Song, et al., 2007). These targeting agents 
have been reconstituted into a LDL core. Transmission electron microscopy has 
confirmed that these conjugates retain the size and shape of native LDL and were 
preferentially taken up by tumor tissues (De Vries, et al., 1999). Although LDL has 
proven to be a useful vehicle for the delivery of lipophilic drugs and diagnostic agents to 
tumors, its clinical application in cancer is limited to LDL receptor related diseases 
because many tumors do not over express LDL receptors (Dolmans, et al., 2003; Zheng, 
et al., 2005;Fodinger, et al., 2000; Bailey and Gregory, 1999).  
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Antibodies and serum proteins. To enhance tumor selectivity. Antibodies can be 
used as targeting vehicles when being conjugated to PS (Mayo, et al., 2003). The 
conjugation of a PS to an antibody retains the photosensitizing properties and the 
conjugates bind to targeted cells more strongly than the native PS. Bhatti etal (Bhatti, et 
al., 2008) introduced a system in which multiple PS were covalently attached to single 
chain variable fragments. The resulting photoimmunoconjugates not only retained 
photophysical properties but also were more potent than any of the individual PS with 
respect to tumor cell killing capacity. Another study showed that multiply loaded 
bioconjugates composed of transferrin and hematoporphyrin when combined with 
luminol can significantly improve the specificity and efficiency of PDT for 
erythroleukemic cells by a factor of almost seven fold (Laptev, et al., 2006). Malatesti et 
al (Malastesti, et al., 2006) synthesized a cationic 5,15-diphenyl porphyrin-monoclonal 
antibody (DPP-MAb) conjugates via an isothiocyanate linkage. The resulting DPP-Mab 
conjugate were photodynamically inactive. Chlorin e6-monoethylenediamine monoamide 
has been studied by the Hasan laboratory (Soukos et al, 1998). Theses conjugates were 
synthesized with various linkers including dextran, poly-L-lysine to increase the 
photosensitizer:MAb ratio. It was shown that ratios between 24-36 impaired 
immunoreactivity. These compounds also showed increased tumor selectivity and 
phototoxicity, yet complete removal of the tumor cells were not consistently found. 
Steroids and hormones. Many steroid hormones have been conjugated to various 
PS to increase selectivity, based on the hypothesis that the overexpressed steroid 
receptors that in hormone-sensitive cancer cells can serve as the targeting site. Sharman 
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et al. (Sharman, et al., 2004) have discussed the use and efficacy of 2-methoxyestradiol, 
glucocorticoids, lovastatin, estrogens, androgens, progesterone, glucocorticosteroids, 
thyroid hormones and retinoic acid (Golab, et al., 2003; Cowled, et al., 1985; Biade, et 
al., 1993; Aranda and Pascual, 2001). All of these molecules can bind with high affinity 
to a specifc member of the nuclear hormone receptor superfamily (Josefen and Boyle, 
2008). Steroid receptors located on the nuclear membrane attracted and directed their 
ligands into cancerous cells where these receptors are overexpressed.  
 Hormone-responsive tumor cells, especially breast tumor cells that naturally 
overexpress estrogen receptor, can be targeted for the selective delivery of estrogen-
porphyrin conjugates for targeted PDT in breast cancer. Although many steroid-
photosensitizer conjugates can effectively increase the phototoxicity within targeted 
tumor cells, their low binding affinity to the targeted steroid receptors remains a problem 
(Sharman, et al., 2004). High phototoxicity often associates with low selectivity, and vice 
versa. For example, when chlorin e6-estradiol conjugates was introduced into the 
estrogen receptor positive MCF-7 breast cancer cells, it proved to be highly photoactive 
(James, et al., 1999). However, the binding affinity of this conjugate to the estrogen 
receptors was about 300 times less than estradiol (Swamy, et al., 2002). One the other 
hand, steroid-PS conjugates such as tetraphenylporphyrin-C11-β-estradiol can exhibit 
high selectivity toward steroid receptor positive cancer cells, but is phototoxic activity 
was insufficient and ineffective when being test in MCF-7 breast cancer lines (Aranda 
and Pascual, 2001; James, et al., 1999, Swamy, et al., 2002). Tamoxifen (TAM), an 
antiestrogen, covalently linked to pyrophenophorbide (a porphyrin derivative) via a seven 
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carbon long tether. Results of the estrogen receptor (ER) binding assay showed that this 
TAM-pyropheophorbide conjugates showed specific binding affinity for ERα and 
displayed a strong cell killing properties in MCF-7 breast cancer cells (Fernandez, et al., 
2006). In another study, four conjugates of C17-α-alkylnulestradiol and chlorin e6-
dimethylester were synthesized with varying tether lengths. One of the conjugates was 
efficiently taken up selectively by breast cancer cells and showed were phototoxic upon 
irradiation with red light (Azria, et al., 2009; Swamy, et al., 2006). 
 Folate. A wide variety of photosensitizer drug carriers including liposomes, 
LDLs, and small oligonucleotide fragments have been conjugated to folate and evaluated 
for the effectiveness of folate receptor (FR) targeted delivery with varying degree of 
success. The cell membrane FR can be used as a selective target for PS drug delivery. 
The FR α isoform is usually amplified in epithelial cancers, while over expression of the 
FR β isoform is commonly found in myeloid leukemia and activated macrophages 
associated with chronic inflammatory disease (Zhao and Lee, 2008). Conjugates of folic 
acid can be taken up by cancer cells via receptor mediated endocytosis (Reddi, 1997).  
These conjugates have been shown to enhance the uptake ratio and antitumor activity of 
the PS both in vitro and in vivo. One of the problems with most PS currently used in PDT 
clinical trial is their low tumor-to-normal epithelial uptake ratio. This is especially the 
case with m-THPC. In order to overcome this limitation, Gravier et al. (Gravier, et al., 
2008) have reported on the synthesis of an m-THPC-like photosensitizer conjugated to 
folic acid. Using optical fiber fluorimetry, the enhanced selective accumulation of this 
18 
 
conjugate was demonstrated in FR α positive KB mouse tumor cells 4 h after injection 
and the resulting tumor-to-normal tissue ratio was 5:1. 
 FR-mediated liposomal delivery has also been shown to enhance antitumour 
efficacy of the photosensitizer doxorubicin both in vitro and in vivo (Pan and Lee, 2004). 
These FR-targeted liposomes could serve as carriers directing many genes and antisense 
oligodeoxyribonucleotides to FR-positive tumor cells. Both solid tumors and leukemia 
can potentially benefit from this approach (Reddi,1997; Pan and Lee, 2004). Studies have 
also demonstrated the role of folic acid conjugation in rerouting the resulting conjugate 
bearing an LDL carrier molecule from its natural receptor to cancer cells through folate 
receptors (Glickson, et al., 2009; Preise, et al., 2009). 
 Vascular targeted-PDT. To induce tumor growth, tumor tissues need to develop a 
vascular system based on existing host blood vessels for nutrients delivery and the 
removal of metabolic wastes. Vascular-targeted photodynamic therapy (VTP) makes use 
of the intravascular excitation of PS to produce cytotoxic ROS, which are the mediators 
through which VTP initiates acute local inflammation inside the illuminated area 
accompanied by tumor cells death (Reddi, 1997). Unlike other PDT techniques, PS used 
in VTP are activated in the vasculature. Various mechanisms of VTP-mediated tumor 
eradication through immune response induction has been examined. Using the PS WST-
II, Preise et al. (Fleshker, et al., 2008) has shown that long-lasting systemic antitumor 
immunity was induced by VTP that activates both cellular and humoral components and 
that VTP can be used in conjunction with immunotherapy for the enhancement of host 
antitumor immunity. To increase the overall success rate of VTP, an assessment for 
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successful VTP of solid tumor 24 h post treatment is needed to allow for a second 
treatment in case of failure. For example, the treatment of carcinoma tumors in mice by 
VTP with the photosensitizer WST-II was used to enable fast assessment of treatment 
success after 24 h. The mice that signified treatment failure, featuring various levels of 
subsequent tumor re-growth, were treated again and the overall successful VTP rate 
increased to over 90% (Eggener and Coleman, 2008). Two common vascular-targeting 
photosensitizers being clinically used today are verteporfin and palladium 
bacteriopheophorbide (WST09 or Tookad) (Trachtenberg, et al., 2008). It was shown that 
Tookad-VTP can produce large avascular regions in the irradiated prostate, resulting in a 
complete negative biopsy response at high light doses (Di Stasio, et al., 2005). 
 Lectins and saccharides for PS conjugates. Lectins are cell adhesion molecules 
that have been known to play a role in recognizing cell surface carbohydrates of cancer 
cells, including liver, breast, prostate, lung, and bile duct cell types. Thus, they are 
popular targets for developing glycoconjugated photosensitizer drugs (Frochot, et al., 
2003). Cancer cells generally overexpress monosaccharide transporters at the surface of 
their plasmic membrane (Taquet, et al., 2007). This will allow for increased PS solubility 
and enhanced selectivity. Mono-glucosylated porphyrins and mono-glucosylated chlorin 
e6 have been shown to accumulate mainly inside the endoplasmic reticulum in human 
colon adenocarcinoma cell line HT29. Improved cellular uptake and increased 
photodynamic activity in terms of singlet oxygen quantum yield and a high extinction 
coefficient value were also demonstrated (Zheng, et al., 2001; Chen, et al., 2004). In 
another experiment, β-galactose was conjugated to the PS, purpurinimides. This PS-
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saccharide complex is recognized by galectin-l in vitro and exhibits an increase in 
photodynamic efficacy (Hamblin, et al., 2000). Non-hydrolyzable saccharide-porphyrin 
conjugates have also been synthesized using a tetra(pentafluorophenyl)-porphyrin and a 
thiol sugar derivative. These saccharides-porphyrin conjugates showed a varying degree 
of PDT success across different types of malignant cancer cells (Sutton, et al., 2002). 
 Targeting with peptides.  Peptides are of interest for targeted PDT due to their 
cell penetrating properties and their affinity to specific receptors (Taquet, et al., 2007). 
Peptide-PS generally retain the photophysical properties of the PS, yet the quantum yield 
of singlet oxygen is often lowered (Taquet, et al., 2007).  The arginine-glycine-aspartic 
acid (RGD) peptide motif has been shown to improve PDT targeting efficiency and 
reduce the side effects of accumulated photosensitizers in non-target tissue (Taquet, et 
al., 2007). RGD conjugated to tetraphenylchlorin (TPC) was shown to be internalized 80-
100 more times than TPC alone after 24 h and it was shown to bind specifically to the 
overly expressed avß3 integrin on the surface endothelial cells in tumor neovasculature. 
But the RGD-TPC had a two-fold decrease in singlet oxygen production. Cyclic RGD 
peptide conjugated to photosenstizer PpIX was shown to have an increase cell 
accumulation over PpIX, but when tested in vivo it accumulated in the liver and did not 
enhance PDT (Taquet, et al., 2007). In another study, Frochot et al. (Zheng, et al., 2001) 
synthesized a conjugate of porphyrin and the avß3 integrin specific peptide RGD. The 
higher photodynamic efficiency observed was correlated with greater cellular uptake of 
the conjugate. In vitro results have confirmed that PS with linear or cyclic RGD motifs 
are much more potent in targeting tumor endothelial cells due to its high affinity to avß3 
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integrin receptors commonly found in many types of cancer and may potentiate the effect 
of vascular PDT in vivo as well. 
The RGD motif has also been employed in PDT that involves tumor targeting 
with adenoviral proteins because the penton base of the adenovirus type 2 capsid protein 
contains the RGD sequence. Allen, et al. (Taquet, et al., 2007) has covalently coupled the 
PS tetrasulfonated aluminum phthalocyanine (AlPcS4) to various adenovirus capsid 
proteins, and the AlPcS4A protein complex has been shown to induce greater 
phototoxicity than the unconjugated AlPcS4A. This suggests that the high affinity 
RGD/receptor complex can be potentially used as another targeting vehicle to deliver 
photosensitizers to the appropriate tumor cells. 
Peptides can also be used to target a specific subcellular compartments. Nuclear 
localization sequence (NLS) has been used to target the nucleus although attempts to 
detect the PS-NLS in the nucleus have failed (Taquet, et al., 2007). A major issue with 
PS-peptide conjugates in vivo is their lack of stability in the bloodstream (Taquet, et al., 
2007).  
Nanoparticles. Two general strategies exist for using nanoparticles as a 
photosensitizer carrier system. The first is using biodegradable nanoparticles, made of 
polymers readily degraded in a biological environment, in which the photosensitizers 
can be released from the nanoparticle and irradiated to produce single oxygen. The 
secondly strategy is to use non-biodegradable nanoparticles in which the photosensitizer 
is not necessarily being released from the system, but the singlet oxygen could diffuse 
freely in and out of the nanoparticle carrier system (Spenlenhauer, et al., 1989). 
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 One of the most commonly used biodegradable nanoparticle is the aliphatic 
polymer poly(DL-lactic-co-glycolide) (PLGA) nanoparticle. The mechanism of which 
involves a size-dependent hydrolytic process. Nanoparticles of less than 300 µm in 
diameter undergo a homogeneous degradation while larger particles show a 
heterogeneous degradation in vivo and in vitro (Gomes, et al., 2005). Polymeric PLGA 
nanoparticles have been loaded with various PS including bacteriochlorophyll-a (BChl-
a) (Gomes, et al., 2007; McCarthy, et al., 2005), p-THPP, m-TPPPL, m-TTP (Ricci-
Junior and Marchetti, 2006), zinc(ll) phthalocyanine (ZnPc) (Zeisser-Labouebe, et al, 
2006), hypericin (Hy) (Kopelman, et al., 2005). The delivery process has been shown 
taking place in two steps: (1) adhesion of the particles to the cell surface followed by 
(2) the release of the PS, which caused detectable photodamage of the targeted cellular 
surface after laser irradiation (Bechet, et al., 2008). PLGA nanoparticles loaded with p-
THPP achieved vascular targeted PDT, they are limited in their loading capacity 
(Taquet, et al., 2007). In addition, these nanoparticles lose their PS content in aqueous 
solution at a steady rate (Taquet, et al., 2007).  
 Many non-degradable nanoparticles have also been synthesized, although their 
application in targeted PDT is still limited. The ability of non-biodegradable 
nanoparticles to serve as multifunctional platforms proved to be quite effective in the 
diagnostic and treatment of cancer. For example, in a brain cancer study (Sutton, et al., 
2002), a non-degradable polyacrylamide nanoparticle platform containing Photofrin® 
with a PEG surface coating, and the cellular targeting agent (the integrin-targeting RGD 
peptide) was synthesized. This multifunctional nano-platform was capable of diagnosing 
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brain cancer due to the presence of an associated magnetic resonance imaging (MRI) 
contrast enhancer. In in vivo experiments, the MRI contrast agent could be used to 
monitor changes in tumor diffusion, tumor growth and tumor load (Ahmad and Mukhtar, 
2000). Treatment with this PS-nanoparticle system was followed by irradiation of the PS 
and tumor necrosis (Sutton, et al., 2002; Ahmad and Mukhtar, 2000). Most non-
degradable nanoparticles are silica-based or metallic-based. One advantage of metallic-
based nanoparticles, in contrast to their silica-based counterparts, is that they can be 
confined to an extremely small particle size of only a few nanometers while their large 
surface area can facilitate a large number of photosensitizer molecules, which resulted in 
an increased singlet oxygen diffusion (Doughtery, et al., 1998). 
Folate Directed, Protein Based Targeted PDT 
 Our laboratory aims to develop a third generation PDT agent that will provide 
increased selectivity for tumor cells, and a greater concentration of PS at the site of 
action, using a L.E.D. light source. We will generate folate directed PDT agents that will 
target the FR on cancerous cells. Many cancers overexpress the FR, therefore attaching 
folate to a PS should enhance selectivity, and delivered into the cell via receptor mediated 
endocytosis.  
 In addition to poor specificity, the light needed to activate many PDT agents can 
only penetrate tissues between 0.5-3 cm. This drastically limits the types, size, and 
location of cancers that can be treated. Utilizing a PS that has absorbances in the 
optimum therapeutic window, 600-800 nm, with high extinction coefficients, will allow 
for deeper tissue penetration of light and enough energy to produce singlet oxygen. Our 
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PS of choice is Chlorin e6 (Ce6), a relatively inexpensive commercially available dye. 
Ce6 will lead to significant cellular death due to its absorption maxima at 660nm and 
corresponding high extinction coefficient of 59,000 M-1cm-1 at that wavelength. This will 
allow for deeper penetration into cells and higher generation of singlet oxygen.  
 We will use bovine serum albumin (BSA) as our carrier. Folate and Ce6 will be 
covalently bound to BSA through amidation reaction. The incorporation of BSA will 
increase solubility and reduce hydrophobicity.  
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CHAPTER TWO 
PURPOSE OF RESEARCH 
The main objective of this research is to develop a folate-directed, protein-based 
photodynamic therapy agent to treat cancerous tumors and to show their effectiveness in 
cell culture and in vivo. We aimed to develop novel photodynamic therapy (PDT) agents 
that specifically target cancerous cells. PDT utilizes oxidative damage to kill these cells.  
Light excites a photosensitizer, which then reacts with oxygen to form a highly reactive 
oxygen species, singlet oxygen.  This singlet oxygen reacts with cellular macromolecules 
to cause lethal damage (Vrouenraets, et al., 2003). We hypothesize that folate (FA) 
conjugation to a photosensitizer will increase the agent’s specificity. Folate receptors are 
overly expressed in epithelial, ovarian, cervical, breast, lung, kidney, colorectal, and brain 
tumors (Zwicke 2012; Parker 2005) Therefore, FA-PDT has double selectivity due to the 
combination of folate-targeting plus limited-area light exposure. The folate containing 
conjugate can be taken up by the cell into the cytoplasm via receptor mediated 
endocytosis.  
In addition to poor tissue specificity of many PDT agents, the light needed for 
excitation can only penetrate tissues between 0.5-3cm (Vrouenraets, et al., 2003). This 
drastically limits the types, size, and location of cancers that can be treated. Utilizing a 
photosensitizer that have absorbances at longer wavelengths in the optimum therapeutic 
window, 600-850 nm, with high extinction coefficients, will allow for deeper tissue 
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penetration of light and enough energy to produce singlet oxygen (Vrouenraets, et al., 
2003). We hypothesized that using chlorin e6 (Ce6), a relatively inexpensive 
commercially available dye, as a photosensitizer will lead to significant cellular death. 
Ce6 has an absorption maximum at 660 nm and corresponding high extinction coefficient 
of 59,000 M-1cm-1 at that wavelength (Dolmans, et al., 2003). This will allow for deeper 
penetration into cells and higher generation of singlet oxygen.  
 Both FA and Ce6 are hydrophobic therefore, we hypothesize by covalently 
attaching FA and Ce6 to bovine serum albumin (BSA), hydrophilicity will increase 
making conjugation chemistry more efficient and delivery to cancerous tumors easier. 
We choose BSA due to its relative stability, low cost, ease of purification, and its high 
number of lysine residues. BSA has between 30-35 free lysines, whose primary amine 
residues can react with the carboxyl groups, 2 and 3, respectively on FA and Ce6 to form 
a stable amide bond. The large number of sites of conjugation provides a platform to 
deliver a greater of number of Ce6 to the cancerous tumor.  
 HeLa cells are an immortal cell line that was derived from cervical cancer cells. 
This cell line is commonly used in cancer research along with a host of other scientific 
quests. Low and Leamon proved in 1991 that the folate receptor on HeLa cells can be 
exploited to deliver folate conjugated macromolecules into the cytoplasm via receptor 
mediated endocytosis. They also proved that macromolecules in the range of 13.7 kDa 
(RNase) to 443 kDa (ferritin) can be internalized into HeLa cells via the folate receptor. 
Therefore, we hypothesize that our folate targeted compound, FA-BSA-Ce6, which is 
well within the size range they explored, should be able to be internalized into HeLa 
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cells, thus making HeLa cells a viable option for cell culture studies. We will explore 
both concentration and light energy, to determine optimal experimental conditions. 
In addition to cell culture, this dissertation will also discuss the use of zebrafish 
for targeted PDT. During embryogenesis zebrafish undergo rapid cell division, which can 
be used as a model for cancer. Zebrafish provides a high throughput organism for in vivo 
studies, as well as their transparent nature allows for insight that cannot be achieved with 
cell culture alone. This use may lead to a new tool for studying zebrafish development. 
This body of work details the synthesis and characterization of folate targeted, 
protein based conjugates, their efficacy in HeLa cell culture, the elucidation of the gene 
expression pattern and confirmation of the folate receptor in zebrafish, and the selective 
targeting of cells during the first 5 days post fertilization of zebrafish embryos.  
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CHAPTER THREE 
BSA BASED, FOLATE DIRECTED PHOTODYNAMIC THERAPY AGENT’S 
EFFECTIVENESS IN HELA CELLS 
Introduction 
 Chemotherapy is one of the most popular course of treatment for cancer. It is 
often coupled with radiation and/or surgery as a two pronged approach to eradicating the 
cancer. There are over 100 chemotherapy drugs available and most work by stopping or 
slowing the growth of rapidly dividing cells throughout the body. This robustness makes 
chemotherapy very effective against cancerous cells yet it also provides an avenue for 
healthy cells to be negatively affected. This leads to numerous unwanted side effects. As 
an alternative to chemotherapy or a method to use less chemo drugs, photodynamic 
therapy (PDT) has become an attractive option. PDT utilizes oxidative damage to kill 
cells.  Light excites a photosensitizer (PS), which activates oxygen to form highly 
reactive oxygen species (ROS), including singlet oxygen, 1O2.  ROS then reacts with 
cellular macromolecules to cause lethal damage (Ahmad and Mukhtar, 2000). In the 
ground state PS have two paired, opposite spin electrons. Upon light activation, one 
electron is promoted to a higher energy orbital, and the PS becomes excited (Robertson, 
2009). The PS can return to a relaxed state by emitting energy as fluorescence. Another 
option is for the PS to undergo intersystem crossing. Intersystem crossing takes the PS to 
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an excited triplet state and from there the PS can participate in two types of reactions 
Type I and Type II (Robertson, 2009). Type I reaction involves the excited PS 
interactingdirectly with a substrate, such as the cell membrane. In this case a hydrogen 
atom is transferred and radicals are formed. These radicals interact with molecular 
oxygen to form reactive oxygen species (Robertson, 2009). In Type II reactions the 
excited PS transfers its energy directly to oxygen to form singlet oxygen, 1O2 (Robertson, 
2009). This 1O2 is toxic to cells and leads to cellular death. Type II reactions are the most 
beneficial to combat cancerous cells because the oxygenated products that are produced 
are more predictable and leads to direct death of the intended cell (Robertson, 2009).  
 Currently Photofrin® (Porfimer sodium) is the most widely used, FDA-approved 
PDT drug for cancer. Photofrin® is a second generation PS that is comprised of a mixture 
of hematoporphryin derivatives. Photofrin® is used to treat esophageal and 
endobronchial cancer. It absorbs light at 635 nm and it is not very selective for cancerous 
cells. This is the case for most of the approved PDT drugs. Many of them have significant 
limitations, primarily low specificity, which causes harm to bystander cells (Dougherty, 
et al.., 1998). They rely on differences in physical properties, such as cellular pH, to 
discriminate between healthy and cancerous cells which leads to poor targeting of tumor. 
In addition, as is the case with Photofrin®, the light needed to excite many PDT agents 
only penetrates tissues to a depth between 0.5-3cm beneath the skin (Fuchs and Thiele, 
1998). This limitation leads to significant limitation of the types, size, and location of 
cancers that can be treated.  
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 Utilizing a photosensitizer that has absorption at longer wavelengths in the 
optimum therapeutic window, 600-850 nm, with high extinction coefficients, will allow 
for deeper tissue penetration of light and enough energy to produce singlet oxygen (Fuchs 
and Thiele, 1998). Chlorin e6 (Ce6), a relatively inexpensive commercially available dye, 
as a photosensitizer will lead to significant cellular death. Ce6 has an absorption 
maximum at 660 nm and corresponding high extinction coefficient of 59,000 M-1cm-1 at 
that wavelength (Oseroff, et al.., 1986). This will allow for deeper penetration into cells 
and higher generation of singlet oxygen.  
 To increase selectivity and effective we propose using folate (FA) as a targeting 
agents for the PS, Ce6.  Many malignant cells overexpress folate receptors in order to 
support its rapid cell division and growth (Bisland, et al.., 1999). FA conjugation to a PS 
will increase the agent’s specificity. Therefore, FA-PDT has double selectivity due to the 
combination of folate-targeting plus limited-area light exposure. The folate containing 
conjugate can be taken up by the cell into the cytoplasm via receptor mediated 
endocytosis. 
 Both FA and Ce6 are hydrophobic. Therefore, in order to increase solubility and 
reduce hydrophobicity as well as provide a scaffold for multiple molecules of Ce6 to be 
delivered to the cancerous cells, we covalently linked FA and Ce6 to bovine serum 
albumin (BSA).  
Materials and Methods 
Reagents.1-ethyl-3-(3dimethylaminopropyl)carbodimide (EDC), bovine serum 
albumin (BSA),  anhydrous dimethyl sulfoxide (DMSO), ethanolamine, fetal bovine 
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serum, folate (FA), Hepes buffered saline (HBS), N-hydroxysuccinimide (NHS), Roswell 
Park Memorial Institute (RPMI), and trypsin/EDTA were purchased from Sigma 
Chemical Company (St. Louis, MO). Chlorin e6 (Ce6) was purchased from Frontier 
Scientific (Logan, UT). Cell Titer Blue Assay was purchased from Invitrogen (Grand 
Island, NY). HeLa cells were obtained from Dr. Stefan Kanzok’s laboratory at Loyola 
University Chicago. All other chemicals used were analytical grade and used without 
further purification, unless otherwise specified.  
 Synthesis of BSA-Ce6, BSA-FA, & FA-BSA-Ce6. Ce6 and FA both contain 
multiple carboxyl groups (three and two respectively). BSA is a 67 kDa single 
polypeptide that has 60 lysine residues.  Of the 60 lysine residues, 30-35 are available to 
react (Huang and Kim, 2004). Carbodiimides are commonly used to activate carboxyl 
groups for conjugation to primary amines. EDC is a water soluble carbodiimide that 
creates a zero length linker between carboxyl and amine groups. EDC coupled with NHS 
reacts with the carboxyl groups on Ce6 and FA to form a semi-stable NHS- ester 
intermediate (Han and Kim, 2004). The lysine residues (primary amine) on BSA reacts 
with the ester intermediate to form an amide bond (Montalbetti and Falque, 2005). 
 Ce6 was placed inside of a 1.5 mL microcentrifuge tube that was covered with 
foil. The dye was dissolved in 200-300 μl of dry DMSO. Next, it was incubated with a 
10-fold molar excess of EDC and a 20-fold molar excess NHS at room temperature for 
30 min.  A 20-fold molar excess of the esterified Ce6 was added dropwise to BSA 
(10mg/ml) that was previously dialyzed in bicarbonate buffer at pH 8.0 The mixture was 
incubated for 24 h at room temperature and quenched with ethanolamine. FA-BSA was 
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prepared in the same manner as BSA-Ce6 with the only exception being that a 10-fold 
molar excess of FA was added to BSA.  The excess Ce6, FA, NHS and ethanolamine was 
removed by dialyzing overnight in phosphate buffered saline (PBS) at pH 7.4.  
 The synthesis of FA-BSA-Ce6 (Figure 8), begins with preparing BSA-FA as 
described above. BSA-FA was exhaustively dialyzed in bicarbonate buffer at pH 8.0. 
Post dialysis a 5, 10, 15, 20, or 30 fold molar excess of esterified Ce6 was added to 
aliquots BSA-FA to determine the optimum Ce6:BSA ratio. The mixtures were incubated 
for 24 h at room temperature. The excess Ce6, NHS and ethanolamine was removed by 
dialyzing overnight in PBS at pH 7.4.  
 
 
Figure 8. Conjugation Schematic. Addition of Folic Acid/Chlorin e6 to BSA. Carboxyl 
groups on folic acid are esterified by reacting with EDC/NHS. The newly formed ester 
reacts with the amine on the lysine residues of BSA to form an amide bond. 
 
 Characterization of conjugates. An acid-acetone precipitation was carried out 
on FA-BSA, BSA-Ce6 and FA-BSA-Ce6 to quantify the number the folates and dyes 
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covalently bound to the protein (Hamblin, et al.., 2000). Briefly, 500 µl of conjugate was 
added slowly while stirring to 5 mL of acidic acetone at 4°C for 4 h. The sample was 
centrifuged at 4000 g at 4°C for 10 min. After centrifuging the supernatant was discarded 
and the pellet was reconstituted in 5 mL of cold acetone, and centrifuged. The 
supernatant was visually inspected after each round of precipitation/centrifuging for hues 
of green and/or yellow. If the supernatant appeared colored, the sample was subjected to 
another round of precipitation. After four rounds of precipitation, an absorption spectrum 
was taken of the supernatant between 220 nm – 900 nm. The spectrum was analyzed for 
any significant peaks, paying close attention to the Ce6 maxima at 400 nm and 660 nm, 
and folate absorption maximum at 363 nm.  This step was repeated until the spectra 
showed no significant peaks above baseline. The remaining pellet was reconstituted in 
1.5 mL of PBS at pH 7.4 and dialyzed against PBS at pH 7.4 for 18h to remove any 
remaining acetone. An absorption spectra was taken of the dialyzed pellet, which 
contains the conjugate, and after correcting for BSA’s slight contribution to the folate 
peak at 363 nm the number of FA and Ce6 molecules covalently attached to the protein 
was determined using folate and Ce6 maxim um absorptions, 363nm and 660nm 
respectively, and corresponding extinction coefficients of 6,197 mM-1cm-1 for folate 
(Kranz, et al.., 1995) and 59,000 mM-1cm-1 for Ce6 (Oseroff, et al., 1986) . 
Determination of ROS production. Photoactivation of Ce6 leads to the 
production of singlet oxygen (1O2) which is a reactive oxygen species (ROS) 
(Wawrzynska, et al.., 2010). ROS is considered to be integral in apoptotic and necroctic 
pathways. Ce6 has been studied for many years and is purported to have a high quantum 
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yield of  1O2 (Douillard, et al.., 2009; Nelson, et al.., 1987, Qian, et al.., 1987; Mojzisova, 
et al.., 2007).To determine if FA-BSA-Ce6 maintains 1O2  production, ρ-nitroso-N, N′-
dimethylaniline (RNO) was used as a singlet oxygen sensor. The production of singlet 
oxygen was monitored by bleaching RNO at 440nm. A 250 μM RNO and 0.03M 
histidine solution was made in D2O. D2O was included to assist in extending the lifetime 
of 1O2  (Klotz, et al.., 1997). 6 µM of unconjugated Ce6 or FA-BSA-Ce6 were dissolved 
in separate vials of 700 μl of 1% DMSO in D2O to maintain solubility of unconjugated 
Ce6. Each solution was added to the RNO solution and bubbled with water-saturated 
oxygen for 10 min. The mixture was placed in a quartz cuvette and irradiated with 44.9 
J/cm2 (8 min) with an 660 nm LED lamp. The absorption at 440 nm (λmax of RNO) was 
monitored every 30 s using a UV-Vis spectrophotometer (Krajlic, et al.., 1978; Mosinger 
and Zdenek, 1997; Muller-Breitkreutz et al.., 1995). 
 Dark cytotoxicity & phototoxicity.  HeLa cells were maintained in Roswell Park 
Memorial Institute (RPMI) media (pH 7.4), supplemented with 10% fetal bovine serum 
(FBS), 2 mM glutamine, and 10 mM HEPES, at 37°C with 5% CO2. Prior to treatment 
the medium was switched to folate deficient RPMI medium. Cells were seeded at an 
initial density of 10,000 cells per well in black-walled 96-well plates. Following seeding 
cells were exposed to the conjugates, BSA-Ce6 or FA-BSA-Ce6, at a Ce6 concentration 
of 1, 2, 5 and 10 µM respectively and incubated for 24 h in the dark. After incubation the 
folate-deficient medium was removed and after several washes the cells were placed in 
folate-containing-RPMI. The cells were then irradiated with a LED lamp (660 nm) for 1, 
2, 4, and 6 min, respectively to deliver 5.6, 11.2, 22.5 and 33.7 J/cm2  respectively. In 
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parallel, an identical control plate was kept in the dark. After incubating for 24 h cell 
viability was determined using Cell Titer Blue Assay Kit (Promega).  
Statistical analysis. Two-tailed student’s t test was used to identify significance 
between means. The level of significance was set to p <0.05. All values stated are 
reported as the mean +/- standard deviation from the mean.  
Results 
Quantification of folates and chlorin e6 molecules bound to BSA. Slight 
modification of published protocols for carboxyl to amine amide bond formation 
(Leamon and Low, 1992), BSA-Ce6 and FA-BSA-Ce6 conjugates were synthesized via 
exposed lysine residues in BSA and free carboxyl groups on Ce6 and FA (Figure 8). BSA 
(10mg/ml) was conjugated to folic acid (FA) using a 10 molar excess of FA to protein. 
Based on the absorbance after dialysis at FA maximum absorption wavelength 368 nm 
and corresponding extinction coefficient of 7410 mM-1cm-1 (Kranz, et al.., 1995) the 
number of folates covalently bound was determined to be two. Ce6 has an absorption 
maximum at 660 nm and corresponding extinction coefficient of 59,000 M-1cm-1 
(Oseroff, et al.., 1986) at that wavelength. A UV-vis spectra was taken after the final 
dialysis, and the number of Ce6 molecules covalently attached to FA-BSA was 
determined. As shown in Table 2, 5:1, 10:1, 20:1 and 30:1 ratio of Ce6 to protein 
produced four, six, ten, and ten molecules covalently attached respectively. 
Porphryin based dyes, such as Ce6, can potentially strongly interact non-
covalently with serum proteins (Mew, et al.., 1983). To ensure that all excess Ce6 
molecules in addition to FA were removed an acetone extraction was also performed on 
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each of the conjugates. After conjugation, an aliquot was added dropwise to cold acetone, 
and the pellet was analyzed via absorption spectroscopy. The resulting number of FA and 
Ce6 that were determined to be covalently attached matched the results from exhaustively 
dialyzing the conjugates. Based on the results, acetone extraction was deemed to be 
unnecessary and the conjugates were dialyzed in PBS post conjugation. Based on the 
results, a ratio of 20:1 was used for FA-BSA-Ce6 synthesis. 
  
 
 
 
 
 
 
Table 2. Number of Dye Bound. The number of Ce6 molecules was determined using 
varying rations of photosensitizer to protein. Ten molecules were covalently attached 
using 20:1 and 30:1, therefore, 20:1 was chosen. 
 
Singlet Oxygen Production due to photoactivation. Ce6 produces a significant 
amount of singlet oxygen (Fernandez, et al.., 1997). To determine if Ce6 maintains its 
output of singlet oxygen once conjugated to FA-BSA, samples of FA-BSA-Ce6 and Ce6 
(both samples contained the same Ce6 concentration) were mixed with RNO (a singlet 
oxygen quencher) and was irradiated with a L.E.D. lamp at 660 nm for 8 min. An UV-
Vis spectra was taken every 30 s monitoring the absorption at 440 nm (Figure 9). As 
singlet oxygen is quenched by RNO, there is a reduction in the absorption at 440nm. The 
decrease in the peak was monitored until the absorbance was around 0.100.  
Ce6:BSA # of Ce6 
5:1 4.2 
10:1 6.3 
20:1 10.4 
30:1 10.3 
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Figure 9. Singlet Oxygen Produced from FA-BSA-Ce6. Singlet oxygen quencher, RNO, 
was used to monitor the production of singlet oxygen of FA-BSA-Ce6 upon irradiation at 
660nm between 0 min and 8 min. 
 
FA-BSA-Ce6 dark cytotoxicity. The cells were exposed to the conjugates for 24 
h, washed and then incubated for another 24 h, after which cell viability was measured 
using Cell Titer Blue Assay Kit (Figure 10), a fluorescence assay in which viable cells 
exhibit a higher fluorescence than non-viable cells. Percent survival was determined by 
comparison to cells exposed to media only. BSA-Ce6 at a concentration of 10 µM had a 
98% (+/- 5   %) cell survival rate. FA-BSA-Ce6 at 1µM, 2 µM, 5 µM, and 10 µM 
concentrations were also assayed for dark cytotoxicity. The respective survival rates were 
as follows: 100 % (+/- 2 %), 93 % (+/- 1.5 %), 98 % (+/- 3 %), 98 % (+/- 2 %) (Figure 
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10). There was no statistical difference between media only cells (control) versus any of 
the test wells. All of the conjugates cell survival rates were above 93% when compared to 
control. 
 
Figure 10. Dark Cytotoxicity Results of Conjugates and Controls. Based on control cells 
all conjugates are not significantly different. 
 
Cell death via photoactivation of FA-BSA-Ce6. The viability of media only 
cells was set at 100%, and all conjugates are reported in comparison to those cells. Cell 
viability for 1µM, 2 µM, 5 µM, and 10 µM FA-BSA-Ce6 was assayed at 5.6, 11.2, 22.4, 
and 33.7 J/cm2 of light, in addition to 10 µM BSA-Ce6. Across all times of light 
irradiation BSA-Ce6 maintained above 92% cell survival (Figure 11).   
No significant cell death resulted for 1µM of FA-BSA-Ce6 at any of the 
irradiation energies. The lowest viability for FA-BSA-Ce6 at 2 µM was 74% with 2 
minutes of light irradiation. This was the lowest viability for that concentration, which 
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was significantly different than at 1 minute, but not significantly different from 4 minutes 
of light (based on standard deviations).  
While the lowest viability for FA-BSA-Ce6 at 2 µM was 74% with 2 min of light, 
the highest viability for both 5 µM and 10 µM FA-BSA-Ce6 was 76% with 1 min of 
light. 5 µM and 10 µM samples show significant difference from the controls starting at 2 
minutes of light, yet they do not show any statistical difference from one another for the 
other light energies (Figure 12). 5 µM FA-BSA-Ce6 caused the most cell death with 4 
min of light which resulted in 5.3% cell survival. 10 µM FA-BSA-Ce6 caused the most 
cell death at 4 min light as well, which resulted in 3.9% cell survival. 
 
 
Figure 11. Phototoxicity of Controls: BSA or BSA-Ce6 showed significant cell death in 
comparison to cells exposed to media only. 
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Discussion 
An effective photodynamic therapy agent will be phototoxic but not cytotoxic in 
the dark. In an attempt to maximize the efficiency of Ce6 conjugation to BSA we varied 
the ratio of Ce6:BSA. There was a lack of increase in Ce6 conjugation with 30:1 ratio in 
comparison to 20:1. In 2004 Huang and Kim reported on the use mass spectrometry 
coupled with lysine specific cross-linkers to analyze the tertiary structure of BSA. In their 
study the were only able to crosslink 34 of the 60 lysines that are present in BSA (Huang 
and Kim, 2004). The lack of increase in Ce6 conjugation with 30:1 vs 20:1 ratio could be 
due to steric hindrance of the available lysines. Thus, a 20:1 ratio of Ce6 to protein was 
chosen, and based on UV-Vis spectra conjugation of both folate and Ce6 was successful.  
To ensure that Ce6 maintained its ability to produce singlet oxygen, its production 
of singlet oxygen was monitored via a singlet oxygen quencher. The results from this 
experiment confirmed that upon conjugation to FA-BSA, Ce6 produces singlet oxygen. 
The effectiveness of FA-BSA-Ce6 as a photodynamic therapy agent was 
examined in comparison to media-only cells and BSA-Ce6 (Figure 11).  BSA-Ce6 was 
shown to not be phototoxic or cytotoxic at 10 µM concentration and at all light intensities 
assayed. This is a significant finding because free Ce6 at significantly lower 
concentrations have been proven to be cytotoxic and we report 98% cell survival rate of 
BSA-Ce6. Conjugating Ce6 to BSA increases its solubility and decreases it 
hydrophobicity. This is the most apparent reason why BSA-Ce6 did not show any 
significant cell death, while in the literature Ce6 demonstrates cytotoxicity. 
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 As shown in Figure 12 cell survival is both concentration and light dose 
dependent. As the concentration of FA-BSA-Ce6 increase and as light exposure time 
increases, cell survival decreases. Interestingly, the same effects are not seen with BSA-
Ce6 (Figure 11). Light irradiation time does not affect percent survival. The only 
difference between the two conjugates is the targeting moiety, folate.  This data 
combined with the ROS production data, it can be concluded that the conjugate is being 
taken up via receptor mediated endocytosis.  
We have demonstrated that conjugation of FA and Ce6 to BSA provides an effective 
PDT agent that is specifically taken up into the cells via receptor mediated endocytosis. 
The conjugate is both dose time and concentration dependent. Thus the higher the 
concentration and the longer light irradiation, the less cell survival. Concentrations less 
than or equal to 2 µM are not effective at killing cells in culture. In contrast there is no 
benefit in using 10 µM FA-BSA-Ce6 due to 5 µM FA-BSA-Ce6 providing essentially the 
same magnitude of cell death. FA-BSA-Ce6 offers potential benefits not seen with 
approved PDT agents. The main difference presented is the ability to target cells that 
upregulate the folate receptor. Thus combining limited light area exposure and the 
targeted conjugated, FA-BSA-Ce6 offers double selectivity.  
 In 2015 Donghong Li et al. synthesized a new a m-tetra(Hydroxyphenyl)chlorin 
(m-THPC) derivative based PS called, PS1, and covalently attached folate to PS1 via 
PEG. m-THPC is approved for use in Europe, Norway, and Iceland as PDT agent under 
the name Foscan (5).  m-THPC has a maximum absorption at 650 nm and without a 
targeting moiety such as folate, it demonstrates poor selectively. Li reported on improved 
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tumor selectively over m-THPC without folate. HeLa cell culture experiments with 15.2 
µM PS1 and light dosages up to 36 J/cm2 resulted in cell viability for all light dosages 
above 10%. When the concentration was varied up to 147 µM and the light was constant 
at 18 J/ cm2, cell viability was above 20% for all concentration tested. Using almost three 
times less of PS, and three times less light, our 5 µM FA-BSA-Ce6 with 11.2 J/cm2  of 
light, produced similar results.  
 In another study folate-targeted PEGylated liposomes with m-THPC were 
synthesized and tested for its effectives as a PDT agent (Moret, et al., 2013). In this study 
the results for phototoxicity in KB cells were significantly better than m-THPC alone and 
the work PS1. Liposomes have previously been shown to be a good encapsulator and 
carrier of m-THPC (Moret et al., 2013). Moret and colleagues synthesized two m-THPC 
liposome conjugates with two different PEG lengths. While no increase of uptake of was 
seen with the smaller 2000 kDA PEG over a zero length linker, uptake was increased 
with the larger 5000 kDa PEG. Their folate targeted conjugate produced less than 10% 
cell survival with only 2.4 µM of conjugate and .8 J/cm2 of light. This is a significant 
improvement in comparison to our conjugates and PS1. But, they also discovered that the 
untargeted and targeted conjugates produced similar phototoxicity. Un-targeted, BSA-
Ce6 was not phototoxic to cells.  
Lee and Low showed that PEG lengths can affect the photo-killing capacity and 
uptake of PDT agents. PS1 was synthesized with a 75 kDa PEG and produced little cell 
death in comparison to Moret and colleagues conjugate. Laura Donahue and colleagues 
(unpublished) has synthesized a 2000 kDa FA-PEG-Ce6 PS that shows promise as a good 
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PDT agent at lower concentration than FA-BSA-Ce6, yet FA-PEG-Ce6 showed some 
cytotoxicity in the dark. Based on these findings with PEG linkers, it may be beneficial to 
link folate to BSA using a 2000-5000 kDa PEG to increase phototoxic at lower 
concentrations while maintaining minimal dark cytotoxicity.  
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CHAPTER FOUR 
EXPRESSION AND FUNCTIONAL CHARACTERIZATION OF THE FOLATE 
RECEPTOR DURING ZEBRAFISH EMBRYOGENESIS 
Introduction 
Folate is a well-studied B vitamin commonly referred to as Vitamin B9.  This 
vitamin is necessary for cell maintenance and division due to its nature as a methyl donor 
required for the synthesis and modification of DNA, RNA, and the amino acids serine 
and methionine (Choi and Mason, 2000; Keleman, 2006).  Folate deficiency during 
human fetal development can lead to neural tube defects (Botez and Reynolds, 1979; 
Clarke, et al.., 1998; Reynolds, 2002; Seshadri, 2001). The British Medical Research 
Council sponsored research that showed that women who had prior neural tube defect 
affected pregnancy reduced the risk of having a subsequent neural tube defect affected 
pregnancy by 70% when they supplemented their diets with 4.0 mg per day of folic acid 
(Wala and Sheldon, 1991).  
 Interestingly, folate can be both a cancer protectant and a pro-tumor agent 
(Meenan, et al.., 1997; Willet, 1994; Giovannucci, et al., 1993; Farias, et al.., 2015; 
Zwicke, et al.., 2012). This discrepancy seems to lie in the balance of the amount of 
folate in the system and its bioavailability to cells. During normal cell differentiation in 
humans, the ability of each cell to import folate is controlled by the protein Folate 
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Receptor 1 (FOLR1). In many tumor cells, the FOLR1 protein is overexpressed, 
suggesting a possible target for anti-cancer therapies (Yoo and Park, 2004; Briggs, 2002 
The teleost Danio rerio (also known as the common zebrafish) has become a 
popular model organism for studying vertebrate development and disease due to its 
functionality and the relative ease with which it is possible to subject them to standard 
molecular, genetic, and embryological manipulation (Kao, et al.., 2014). As an example, 
many of the neural tube defects due to folate deficiency in humans have also been 
documented in zebrafish (Blair, et al.., 2005). Approximately 71% of human genes have 
at least one zebrafish orthologue, and 47% of these have a direct, one-to-one relationship 
with their zebrafish counterpart (Kao, et al.., 2014). 
We have defined the expression pattern of zgc:165502, the zebrafish orthologue 
of the human FOLR1 gene, during embryogenesis using reverse transcription polymerase 
chain reaction (RT-PCR), and whole mount in situ hybridization (WISH). This 
expression pattern will allow researchers in multiple fields the ability to study the 
endogenous zgc:165502 gene as expressed during embryogenesis. 
Methods 
Zebrafish care and husbandry. Zebrafish were maintained at Loyola University 
Chicago. All studies were performed with the approval of the Institutional Animal Care 
and Use Committee (IACUC). Wild-type embryos were raised and staged as described in 
Kimmel et al., 1995.  Post-gastrulation stages were treated with 0.005% 1-phenyl-2-
thiourea (PTU) solution to prevent melanin pigment from developing. Embryos older 
than 24 h post fertilization (hpf) were treated with fresh PTU solution once a day. Once 
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the embryos reached the desired stage, they were dechorionated manually if necessary, 
anesthetized with 0.2% Tricaine pH 7.0, then fixed in 4% paraformaldehyde (PFA) in 
PBS pH 7.0 at 4°C.  After fixing, the embryos were washed four times with phosphate 
buffered saline with 0.1% Tween-20 (PBST). After washing, the embryos were placed in 
100% methanol (MeOH) and stored at −20 °C. 
Reverse-transcription polymerase chain reaction (RT-PCR). RT-PCR was 
performed to confirm the presence of the mRNA for the folate receptor at various stages 
of early embryo development: 1- to 2-cell, 256-cell, sphere, germ, shield, 1 days post 
fertilization (dpf), 2 dpf, 3 dpf, and 4 dpf. The primers were designed to anneal to 
sequences in exons on both sides of an intron. Designing the primers in this way allowed 
for differentiation between the PCR products that were amplified by any possible 
genomic DNA contamination, and those amplified by the cDNA created from the RNA 
template. Total RNA was isolated from 50 staged embryos using a TRIzol reagent (Life 
Tech) and purified using a Direct-zol kit and its corresponding protocol (Zymo 
Research). Of the resulting total RNA, 1.5 µg from each embryo stage was reverse 
transcribed using oligo-dT primers (Integrated DNA Technologies) and a SuperScript III 
Reverse Transcriptase kit (Life Tech) to generate first-strand cDNA. One microliter of 
cDNA from each stage was used as a template for the primers 5’-ATT CCT CAC CTG 
AGC AGA ACA TGG-3’ (forward) and 5’-TGA GGT GAG CAC TCA TAG AAG C-3’ 
(reverse) to amplify a 300 bp fragment of the folate receptor cDNA.  The PCR was run 
with 35 cycles of 45 s at 95 ˚C, 1 min at the annealing temperature 62 ˚C, and 1 min at 72 
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˚C.  Ten microliters of the PCR product was analyzed with a molecular weight marker 
(Hi Lo ladder, New England BioLabs) on a 1% Tris-acetate-EDTA agarose gel.   
In situ hybridization. The complete cDNA sequence of human gene FOLR1 was 
used as a query in a BLAST search of the zebrafish reference genome (Zv10).  This 
yielded a single cDNA clone (7433953) which was obtained as a plasmid clone from 
Open Biosystems.  The fragment was inserted into pCSdest plasmid 22423 (Addgene) 
and linearized using the restriction endonuclease AscI.   A digoxigenin-labeled anti-sense 
probe was synthesized using a RNA labeling kit with SP6 RNA polymerase (Roche).  
The folate receptor sense RNA probe was synthesized and used as a control.  
 Whole mount in situ hybridization was carried out as presented in Sisson and 
Topczewski (2009) and Thisse (2000) using low stringency conditions (50% formamide 
hybridization buffer with a .02% Saline-Sodium Citrate Buffer (SSC) final wash). 
Embryos were placed in 1.5 mL micro-centrifuge tubes, and rehydrated using serial 
dilutions to replace MeOH with PBST (75% MeOH:25% PBST, 50% MeOH:50% PBST, 
25% MeOH:75% PBST, 100% PBST).   Next, embryos staged between 1 dpf and 4 dpf 
were digested using a solution of 1 µL Proteinase K in 2 ml PBST. Embryos that were 
staged at 1 dpf were digested for 5 min and embryos staged at 2 dpf and 3 dpf were 
digested for 30 min. 4 dpf embryos were digested for 45 min. After digestion the 
embryos were placed in 4% PFA for 20 min, and then transferred into PBST.  The 
embryos were pre-hybridized for 3 h with 500 µL hybridization buffer (Hyb+) that 
contained: 50 mL formamide, 25 ml 20X saline-sodium citrate buffer, 5 mg heparin, 50 
mg tRNA, 100 µL 0.1% Tween-20, and 460 µL l 0.1M citric acid. During pre-
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hybridization the embryos were kept at 70°C. After 3 h, the embryos were removed from 
the incubator, and two embryos from each stage were placed in a single micro-centrifuge 
tube for blocking. After this, 300 µl of Hyb+ containing 500 ng of anti-sense probe was 
added to each tube (except for the blocking embryos) and kept at 70°C overnight. The 
blocking embryos were treated the same as the other samples except they were void of 
probe. The following day, the Hyb+ with probe was removed, and each stage was moved 
into 0.02% SSC by successive washes of hybridization buffer without tRNA (Hyb-) and 
SSC (100% Hyb-, 75% Hyb-:25% 2X SSC, 50% Hyb-:50% 2X SSC, 25% Hyb-:75% 2X 
SSC, 100% 2X SSC, 100% 0.02X SSC). Following the SSC washes the embryos were 
moved into PBST using serial dilutions. Next all of the embryos except the blocking 
embryos were treated with 500 µl blocking solution (20% fetal bovine serum (Life Tech), 
2% bovine serum albumin (Sigma) in PBST) for 4 h at room temperature. The blocking 
embryos were pre-absorbed with anti-digoxigenin antibody (anti-DIG, Roche) for 4 h. 
After 4 h the pre-absorbed antibody was diluted with fresh blocking solution, and used to 
replace the blocking solution in each tube. The tubes were placed in the dark overnight at 
4 °C. The next day the embryos were washed several times with PBST and freshly made 
staining buffer (0.100M Tris-HCl (pH 9.5) (Sigma), 0.100M NaCl (Sigma), 0.1% Tween 
20 (Sigma)). Following the washes the embryos were stained with 5-bromo-4-chloro-3'-
indolyphosphate (BCIP) and nitro-blue tetrazolium (NBT) staining solution (Roche) and 
placed in the dark at room temperature. The embryos were monitored closely for staining 
and after defined stains developed, the embryos were washed multiple times with stop 
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solution (0.5M EDTA in PBST).  The resulting embryos were imaged using a Nikon 
digital camera fitted to a light stereo microscope using 3.2X magnification.  
Synthesis of folate-bovine serum albumin-rhodamine (FA-BSA-RH). FA-
BSA-RH was synthesized as shown in Figure 13. 10 mg of folate (FA) was placed inside 
of a small, foil-wrapped Eppendorf tube and dissolved in 200-300 μl of anhydrous 
dimethylsulfoxide (DMSO).   This solution was then incubated with a 10-fold molar 
excess of 1-ethyl-3-(3-dimehtylaminopropyl) carbodimide (EDC) and a 20-fold molar 
excess of N-hydroxysuccinimide (NHS) at room temperature for 30 min.  The resulting 
esterified or “activated” FA was added to a 10-fold molar excess of bovine serum 
albumin (BSA) previously dialyzed in bicarbonate buffer at pH 8.0. The mixture was 
incubated for 24 h at room temperature and quenched with ethanolamine. The excess FA, 
NHS, and ethanolamine was removed by dialyzing overnight in bicarbonate buffer at pH 
8.0. Rhodamine B isothiocyanante (RH) was placed inside of a small foil-wrapped 
Eppendorf tube dissolved in 200-300 μl of anhydrous DMSO. A 10-fold molar excess of 
RH was added to the FA-BSA solution that was previously dialyzed in bicarbonate buffer 
at pH 8. The mixture was incubated for 24 h at room temperature and quenched with 
ethanolamine. The excess Rhodamine B was removed by dialyzing overnight in PBS at 
pH 7.4 in the dark. 
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Figure 13. Synthesis Scheme of FA-BSA-RH. Folic acid (1) was reacted with EDC/NHS 
to yield “activated” folic acid. Activated folic acid was reacted with lysine residues on 
BSA to yield FA-BSA (2). (2) was reacted in buffer with RH (3) to yield the final product 
FA-BSA-RH (4). 
 
 Uptake of FA-BSA-RH. Wild type zebrafish embryos were collected at 3 dpf. 
Three embryos were placed in a single well that contained 3 ml of either embryo media, 
BSA in embryo media (50 µM), 50 µM BSA covalently attached to rhodamine (a red 
fluorescent dye) (BSA-Rh), or 50 µM BSA covalently attached to rhodamine and folate 
(FA-BSA-Rh). The wells were placed in a 37°C incubator overnight in the dark. After 24 
h, the solutions were removed and the embryos were washed 3X with embryo media and 
returned to the incubator for 24 h. A total of 20 embryos were assayed with each 
conjugate (BSA, BSA-Rh, FA-BSA-Rh) and embryo media. Fluorescent images were 
taken of each embryo after washes and 24 and 48 h after exposure to the conjugates with 
a stereo fluorescent microscope with 3.2X magnification.  
Results and Discussion 
Conservation of the folate receptor between species. As we are interested in 
utilizing zebrafish as a model of FOLR1 protein structure and function, we first set out to 
52 
 
 
 
determine if the zebrafish zgc:165502 protein was similar to its orthologues. To do this, 
we obtained sequences for 11 identified or predicted chordate Folr1 proteins spanning 
from Ciona intestinalis to Homo sapiens, about 750 million years apart in evolution, to 
generate a phylogenic tree (Hedges, et al.., 2015; Shen, et al.., 2012). We also included 
the two known human paralogs of FOLR1, FOLR2 and FOLR3, in our comparison as an 
out group (Figure 14). Our tree demonstrated that the Folr1 proteins seem to follow the 
predicted vertebrate gnathostome phylogenetic order with higher amino acid conservation 
being observed within a subclass or clade of animals (see Neopterygii and Mammalia in 
Figure 14). Interestingly, the Folr1 amino acid identity conservation is ~50 % for animals 
whose last common ancestor existed about 435 million years ago (Shen, et al.., 2012, 
Antony, 1996). 
The human FOLR1 protein is composed of multiple domains that have been well 
characterized for their biological functions (Zhao, et al.., 2011; Lee, et al., 2011).  These 
domains include an endoplasmic reticulum (ER) signal peptide that is cleaved away after 
protein synthesis, a folate receptor family domain (FRF), a glycosyl-phosphatidyl-inositol 
(GPI) site, and a transmembrane helices domain (THD, Figure 15).  We determined the 
percent identity and percent conservation for each of these domains between the human 
FOLR1 and other vertebrates, including zebrafish (Figure 15). For this comparison we 
used 7 species with published full-length Folr1 proteins. 
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Figure 14. Phylogenetic Tree. FOLR1 proteins follows the predicted vertebrate 
gnathostome phylogenetic order with higher amino acid conservation being observed 
within a subclass or clade of animals.  
 
Of the four domains, the FRF domain had the highest percent identity at 58%.  
Interestingly, many of the amino acids that were conserved between human and zebrafish 
were also found to be conserved in the other vertebrates looked at, suggesting the 
importance of these amino acids. Of particular interest, within the human FOLR1 FRF 
domain are two regions that interact with folate: Folate Binding Sites (FBS) 1 and 2. The 
human FOLR1 FBS1, amino acids 124-128, consists of WRKER. When compared to 
zebrafish, only one amino acid is different (K126 R), which conserves the basic charge 
needed at that location.  The human FBS2, at amino acids 157-162, consists of 
HKGWNW. Again, only one amino acid is different between human and zebrafish 
FOLR1 protein in this region. Asparagine 161 has been changed to aspartate acid, both of 
which are polar. While this change does result in a negative charge at this location it is 
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interesting to note that five of the nine species looked at have aspartic acid at this location 
while the other four have asparagine. Taken together, the high conservation of chordate 
Folr1 proteins and the conservation of critical functional domains between zebrafish and 
human FOLR1 protein, suggest that the zebrafish Folr1 receptor is a good candidate to 
study aspects of vertebrate Folr1 protein function.  
 
 
 
Figure 15. FOLR1 Domains. Percent identity and percent conservation for domains 
between the human FOLR1 and other vertebrates, including zebrafish . 
 
Zebrafish zgc:165502  is a maternally loaded gene that is present during the 
first 4 days of development. To map the expression of the zebrafish folate receptor, we 
used reverse transcription-polymerase chain reaction (RT-PCR) on total RNA prepared 
from the following zebrafish stages: 1- to 2-cell, 256-cell, sphere, germ, shield, 1 dpf, 2 
dpf, 3 dpf, and 4 dpf. Amplification with the designed primers yielded a single band at 
the predicted size of 300 bp (Figure 16) for all stages assayed.  
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Expression was seen before the zebrafish maternal-zygotic transition at the 512-
cell stage (~2.75 h post fertilization), this suggests that zgc:165502 mRNA is maternally 
loaded. These findings correlate with previous research demonstrating that multiple genes 
in the folate metabolic pathway are also present as early as the 1- to 2-cell stage in (Lee, 
et al.., 2012).  
 
 
Figure 16. RT-PCR Results. zgc:165502 is detected in embryonic stages of zebrafish by 
RT-PCR. Each stage assayed presented a single band of 300 bp. 
 
Zebrafish zgc:165502 gene expression during early embryogenesis. An 
antisense and sense riboprobe were generated to perform WISH for the stages that 
presented a 300 bp band in RT-PCR experiments results, as well as to determine the 
spatial temporal expression pattern of the folate receptor of those stages (Figures 17 and 
18). All of the stages tested with the antisense probe demonstrated the presence of 
zgc:165502 mRNA, while sense probe assayed at the same stages were negative. The 
stages from the zygote period (1-cell) up to the late segmentation period (24 hpf) express 
the folate receptor globally (Figure 17). After 1dpf the expression pattern of the 
zgc:165502 gene becomes more localized and specific (Figure 18). By 2 dpf, the late 
pharyngula stage, zgc:165502 expression is seen in the head and heart of the embryo.  
Most enzymes in the folate pathway that have been previously investigated in 
zebrafish were found to be maternally loaded and expressed throughout the early embryo. 
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Inhibition of these enzymes were lethal (Sun, et al.., 2009; Gross and Dowling, 2005; 
Kao, et al.., 2007). The results from this investigation support the findings of these 
studies, and suggest that during these periods the folate receptor is used to support cell 
division although not necessarily cell differentiation.  
 
Figure 17. WISH Results for 1-2 Cell to Shield Stage. zgc:165502 is globally expressed 
(a) 1-2 cell (lateral), (b) 256 cell (lateral), (c) sphere (lateral), (d) 30% epiboly (lateral), 
(e) germ ring (lateral), (f) germ ring (top), (g) shield (lateral), (h) shield (top) 
 
 
 
57 
 
 
 
 
 
Figure 18. WISH Results for 1 dpf to 4 dpf. (a) 1 dpf  is globally expressed (b)2 dpf 
expression is shown in the head (c) expression is shown in the pectoral and caudal fin (d) 
expression is shown in the cloaca and pectoral fin  
 
It has been reported that dihydrofolate reductase (DHFR), an enzyme that plays a 
significant role in folate-mediated metabolism, also has a tissue specific expression and is 
abundantly expressed in the brains of zebrafish during early development (Sun, et al.., 
2011).  DHFR knockdown studies resulted in malformation of the heart (Sun, et al.., 
2010). Other studies that treat embryos with methotrexate (MTX), a folate antagonist, 
showed that rescuing treated embryos with folate resulted in decreasing the cardiac 
deformities (Ma, et al.., 2012). Similarly, studies exposing zebrafish to selenite during 
early embryo development resulted in cardiac and neural defects, but these effects were 
prevented with folate administration (Muralidharon, et al.., 2015). Recently, folic acid 
supplementation has been shown to rescue retinal defects induced by ethanol exposure in 
zebrafish during retinal neurogenesis (1-2 dpf) (Parkin, et al.., 2009). The results of these 
various studies support the conclusion that folate is necessary for cell differentiation. 
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Furthermore, if folate is pivotal at these stages of development, the folate receptor will 
also be necessary and it should be expressed in corresponding regions, which this study 
has shown.  
Zebrafish zgc:165502 gene expression during late embryogenesis. Once the 
embryo reaches the hatching period (2-3 dpf) and continues to the early larval stage (4 
dpf), zgc:165502 expression is seen in specific tissues. The pectoral, dorsal, and caudal 
fins, which begin to develop around 36 hpf, start to show zgc:165502 expression by 2 
dpf. Both development and expression continue through 4 dpf. The expression of 
zgc:165502 mRNA in the fins are consistent with previous studies in literature that 
inhibited DHFR. Using low concentrations of MTX, DHFR was inhibited prior to fin 
development and the embryo exhibited ventral edemas, dorsal curvature, and a shortened 
anterior-posterior axis, along with other defects at this stage (Sun, et al.., 2009). It is 
reasonable to infer from this that folate is essential for the growth and development of the 
fins. 
Development of the digestive tract is initiated around 2 dpf and the gut tube 
development concludes around 4 dpf (Pyati, et al.., 2006) when the cloaca begins the 
final stages of development (Kalli, et al.., 2008). Expression of the zgc:165502 gene was 
detected in the digestive tract at 3 dpf and in the cloaca at 4 dpf. This indicates that the 
folate receptor is present at a time and place during development when folate could be 
needed to sustain the growth and development of the digestive organs, including the 
cloaca.  
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Fluorescent-tagged folate is selectively taken up during development. To 
further confirm the presence of the zgc:165502 protein 3 dpf embryos were treated with 
fluorescent-tagged folate. As a control, embryos were also exposed to the fluorescent 
dye, free of folate (RH). After 24 h of exposure, the embryos were washed with embryo 
media and observed for fluorescence (Figure 19).  Living embryos treated with FA-BSA-
RH demonstrated bright fluorescence in the head and cloaca, which is where we observed 
the presence of zgc:165502 mRNA by WISH. All embryos assayed, including controls, 
fluoresced in the gut. We hypothesized that this was due to the ingestion of the 
fluorescent compounds rather than the zgc:165502 protein being present. To test this 
hypothesis, embryos were placed in media free of fluorescent dyes and folate for 24 h 
after their initial exposure to fluorescent-tagged folate and then observed again. The 
control embryos did not show any residual fluorescence, while the embryos that were 
initially treated with fluorescent-tagged folate showed the same fluorescent profile seen 
previously. These results demonstrate the ability of tissues shown by in situ hybridization 
to have zgc:165502 mRNA also have the ability to internalize folate.  We have shown for 
the first time, that tagged folate can be selectively taken up during embryo development 
in a targeted fashion.  
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Conclusions 
The folate receptor provides information as to when (developmentally) and where 
(spatially) folate can enter into the zebrafish. This study presents the gene expression 
pattern for the zebrafish zgc:165502 gene during embryogenesis. We have shown that the 
folate binding sites (FBS) in the FOLR1 protein in humans are conserved in zebrafish. In 
addition, we have elucidated the globally expression of the folate receptor mRNA in 
zebrafish during the first 24 hpf and the more specific, localized expression during late 
embryogenesis. 
This information can aid in optimizing current treatments for folate specific 
diseases, as well as potentially provide an avenue for researchers to further investigate 
folate specific conditions such as neural tube defects.  
Many cancers have an upregulated folate receptor (Sudimack and Lee, 2000), and 
targeting the receptor has proven to be a useful method to increase specificity and 
potency of drug treatments (Leamon and Reddy, 2004). The use of zebrafish and 
exploiting the folate receptor can help to advance the field of field of cancer research that 
targets the folate receptor. We have demonstrated the ability to exploit the folate receptor 
by use of fluorescent tagged folate.  
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CHAPTER FIVE 
SELECTIVE TARGETTING OF CELLS IN ZEBRAFISH USING FOLATE 
MEDIATED PHOTODYNAMIC THERAPY AGENT 
Introduction 
 The ability to selectively kill cells in a spatiotemporal fashion can provide insight 
into development. Many cancers overexpress the folate receptor (Bisland et al., 1999) 
due to its role in the synthesis of nucleic acids and amino acids (Choi and Mason, 2000; 
Keleman, 2006).  These cells can be selectively targeted by exploitation of the receptor. 
Many agents that specifically targets cancerous cells have been developed (Sudiamack 
and Lee, 2000; Leamon and Reddy, 2004; Lee and Low, 2012). These agents are taken 
up into the cell’s cytoplasm via receptor mediated endocytosis (Sudiamack and Lee, 
2000; Leamon and Reddy, 2004; Lee and Low, 2012). When folate (FA) is conjugated to 
a photosensitizer (PS), both the FA and the PS can be internalized into the cell (Lee and 
Low, 2012). Upon photoactivation the conjugate produces singlet oxygen which damages 
the cell and can lead to cell death. This method of effecting specific cells with PS that 
produces reactive oxygen species is called photodynamic therapy. Since embryonic cells 
also express folate receptors (as shown in Chapter Four) these PDT agents can be used to 
investigate early development. 
 A common PS that has been used in targeted and non-targeted studies is chlorin 
e6 (Ce6) agent that has FA and Ce6 covalently attached to bovine serum albumin,  
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 FA-BSA-Ce6 (discussed in depth in Chapter Three) that is effective as a folate directed 
PDT agent in HeLa cell culture.  
Selective cell targeting coupled with PDT has been studied in many organism, 
and through our search of the literature we believe zebrafish have yet to be used in these 
types of studies. Zebrafish are good candidates for these studies because they are 
vertebrates and they share a high degree of sequence and functional homology with 
humans, their embryos and larvae are transparent making it easy to see the impact of 
treatment with invasive techniques, and they produce a large number of offspring at one 
time (Kao, et al., 2014).  
We have previously elucidated the gene expression pattern for the folate receptor 
during zebrafish embryogenesis (discussed in Chapter Four). Here we report on the 
exploitation of the receptor by selective targeting of cells that express the folate receptor.   
Materials and Methods 
Reagents.1-ethyl-3-(3dimethylaminopropyl)carbodimide (EDC), bovine serum 
albumin (BSA),  anhydrous dimethyl sulfoxide (DMSO), ethanolamine, folate (FA), N-
hydroxysuccinimide (NHS), Rhodamine B isothiocyanate (RH), Acridine Orange (AO), 
were purchased from Sigma Chemical Company (St. Louis, MO). Chlorin e6 (Ce6) was 
purchased from Frontier Scientific (Logan, UT). All other chemicals used were analytical 
grade and used without further purification, unless otherwise specified.  
Zebrafish care and husbandry. Zebrafish were maintained at Loyola University 
Chicago. All studies were performed with the approval of the Institutional Animal Care 
and Use Committee (IACUC). Wild-type embryos were raised and staged as described in 
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Kimmel et al., 1995.  Post-gastrulation stages were treated with 0.005% 1-phenyl-2-
thiourea (PTU) solution to prevent melanin pigment from developing. Embryos older 
than 24 h post fertilization (hpf) were treated with fresh PTU solution once a day. Once 
the embryos reached the desired stage, they were dechorionated manually if necessary, 
anesthetized with 0.2% Tricaine pH 7.0, then fixed in 4% paraformaldehyde (PFA) in 
PBS pH 7.0 at 4°C.  After fixing, the embryos were washed four times with phosphate 
buffered saline with 0.1% Tween-20 (PBST). After washing, the embryos were placed in 
100% methanol (MeOH) and stored at −20 °C. 
Synthesis and characterization of non-fluorescent folate targeted compounds. 
FA-BSA-Ce6 and BSA-Ce6 were synthesized and characterized as detailed in Chapter 
Three. The final products, BSA-Ce6 and FA-BSA-Ce6 were diluted to a final 
concentration of 5 µM and 10 µM using embryo media. 
Selective cell targeting with FA-BSA-Ce6. Wild type zebrafish embryos were 
collected at 2 days post fertilization (dpf) and 3 dpf. Three embryos were placed in a 
single well that contained 3 mL of either 5 µM or 10 µM of BSA in embryo media, BSA-
Ce6, or FA-BSA-Ce6. The wells were placed in a 37°C incubator overnight in the dark. 
After 24 h, the solutions were removed and the live embryos were washed 3X with 
embryo media and returned to the incubator overnight. The following day each embryo 
was irradiated with light at 660 nm for 1 min, 2 min, 4 min, and 6 min which corresponds 
to 5.6, 11.2, 22.5, and 33.7 J/cm2 respectively. Each embryo was determined to be viable 
or non-viable based on response to touch and heartbeat.  A total of 24 live embryos were 
assayed with each conjugate.  
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Confirmation of selective cell targeting.  After the embryos were treated with 
PDT agents as described, they were immersed in 5 μg/ml Acridine Orange (AO) for 10 
min. Following treatment with AO each embryo was imaged for less than 60 s using a 
stereo fluorescent microscope with FITC filter.  
Results 
 Synthesis of conjugates. We have synthesized FA-BSA-Ce6 and BSA-Ce6 as 
previously described in Chapter Three. Briefly, a 10 molar excess of FA that was 
previoulsy esterified using a water soluable carbodiimide was covalently attached to BSA 
via amidation, producing FA-BSA. BSA-Ce6 was produced in th same manner, except 
Ce6 was used in a 20 fold molar excess to BSA. To generate FA-BSA-Ce6, Ce6 was 
covalently attached to FA-BSA, by the same esterification and proceeding amidation 
reaction. The final conjugates, BSA-Ce6 and FA-BSA-Ce6 were dialyzed in phosphate 
buffered saline pH 7.4. Based on UV-Vis absorption spectroscopy it was deteremined 
that each sample produced contained 8 covalently attached Ce6 to BSA, and 2 molecules 
of FA. 
 FA-BSA-Ce6 effectiveness in zebrafish. All embryos treated with BSA-Ce6, 
BSA, and embryo media that were assayed under all conditions discussed were 
determined to be viable for up to 24 h after light exposure. All embryos that were kept in 
the dark remained viable for up to 72 h after immersion in conjugates. Embryos exposed 
to 1 and 2.5 µM FA-BSA-Ce6 were determined to be viable based on reaction to stimulus 
and continued heartbeat for up to 24 h after light exposure.  
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 The results of FA-BSA-Ce6 at 5 and 10 µM on 4 dpf staged embryos (48 h after 2 
dpf embryos were treated with conjugates) are shown in Table 3. Embryos exposed to 1 
min and 2 min of light were all deemed viable. The embryos exposed to FA-BSA-Ce6 at 
both concentrations were non-viable at the end of 4 min and 6 min light exposure.  
Light exposure 
time 
5 uM 10 uM 
1min 0 0 
2 min 0 0 
4 min 24 24 
6 min 24 24 
 
Table 3. Non-viable embryos after PDT treatment. Results of FA-BSA-Ce6 at 5 and 10 
µM on 4 dpf staged embryos. Embryos exposed to light greater than 4 min were all non-
viable, embryos exposed to light under 4 min were all viable after PDT treatment. 
 
 To determine how much light was needed to induce death the trials were video 
recorded. Viability was based on heart beat; once the heart beat could no longer be 
detected the embryo was deemed non-viable. For 5 µM FA-BSA-Ce6 the embryos were 
non-viable on average after 3:42 minu (222 seconds) of continuous light exposure. For 10 
µM FA-BSA-Ce6 the heart beat stopped on average after 3:20 minutes (200 seconds) of 
continuous light exposure.  
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 The results for trials carried out using 5 dpf (48 h after 3 dpf embryos were treated 
with conjugates) were also video recorded. Each trial was video recorded from the onset 
of light irradiation. For both 5 and 10 µM FA-BSA-Ce6, the embryos were reactive and 
visually appeared to be unaffected for light exposure under 3 min. Beginning around 3 
min of light irradiation, 5 dpf embryos began to tremor. Of the 36 embryos treated with 5 
µM FA-BSA-Ce6, all 36 began to tremor and 12 were unreactive to stimulus (did not 
move when touched). 36 embryos were treated with 10 µM FA-BSA-Ce6 and all began 
to tremor beginning at 3 min of light irradiation and were unreactive to stimulus, unlike 
the 5 µM samples. All embryos regained “normal” functions (based on heart beat, 
reaction to touch, phenotype) after 24 h of irradiation. 
 Selective targeting of cells. To visualize cells that were effected by 
photodynamic therapy treatment with 5 and 10 µM FA-BSA-Ce6 we carried out cell 
death assay with acridine orange. The results of trials with 10 µM FA-BSA-Ce6 are 
presented in Figure 19.  As a control we treated embryos staged at 5 dpf in embryo 
media. 5 & 10 µM FA-BSA-Ce6 embryos show significant cell death over control. There 
appears to be no significant difference between 5 & 10 µM FA-BSA-Ce6. 36 embryos 
were assayed, 4 died while determining correct acridine orange concentration. The other 
32 exhibited the same fluorescence pattern. 
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Figure 20. Acridine Orange Assay Results. 5 dpf Embryos treated with FA-BSA-Ce6 
showed significant cell death over embryo media control. There was no observable 
difference between 5 and 10 µM samples. Image presented is indicative of both 
concentrations. 
 
Conclusions 
 Leamon and colleagues (Leamon, et. al, 1993) and many others have shown that 
the folate receptor in cell culture can be exploited with folate conjugated 
macromolecules. We hypothesized that by attaching FA to our BSA-Ce6 carrier 
molecule, the conjugate will be taken up by receptor mediated endocytosis. Previous 
work in our laboratory has proven that not only does zebrafish express the folate receptor 
during embryogenesis (shown in Chapter Four), but they can also take up a FA bound to 
a macromolecule via receptor mediated endocytosis (Chapter Four). In this study we 
synthesized an analog of the fluorescent compound produced in prior studies presented in 
Chapter Three. We replaced the fluorescent dye with a photoactive dye, Ce6. Ce6 is 
known for its large quantum yield of singlet oxygen produced via photodynamic action. 
In this study we set out to exploit the folate receptor in zebrafish to selectively target and 
effect cells that express the folate receptor.   
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 Photodynamic treatment trials were carried out on zebrafish embryos. To ensure 
that the results produced by the light trials were due to the photodynamic action of the 
targeted compounds we carried out these trials in the dark. All embryos exposed to FA-
BSA-Ce6, BSA-Ce6, BSA, and embryo media were viable up to 48 h after exposure. The 
same cannot be said for embryos treated FA-BSA-Ce6 that were irradiated with light. 
From this we can conclude that the results we received from light based studies were due 
to phototoxicity of the conjugates. These results support the results presented in Chapter 
Three, where over 96% of HeLa cells survived after being exposed to the conjugates in 
the dark, yet there was significant cell death upon photoactivation. 
 Photodynamic treatment of 4 and 5 dpf with our targeted agents resulted in all 
embryos treated with lower concentrations, 1 and 2.5 µM FA-BSA-Ce6, and BSA-Ce6, 
remained viable after treatment with up to 6 min of light.  In addition, all embryos that 
were exposed to controls survived as well as embryos exposed to the conjugates but not 
irradiated with light survived. This was to be expected, because based on our results from 
the cell culture trials, where 26% of cells were non-viable after treatment with 2 µM FA-
BSA-Ce6, and less than 2% of cells were non-viable for cells kept in the dark. Therefore, 
we concluded that our conjugates are not cytotoxic in the dark, and 1 and 2.5 µM FA-
BSA-Ce6 combined with 6 min of light does not produce significant cell death. 
 All embryos survived light treatment with 5 and 10 µM BSA-Ce6 and BSA. 4 and 
5 dpf embryos that were treated with 5 and 10 µM FA-BSA-Ce6 survived treatment with 
1 and 2 min of light. 4 dpf embryo treated at this same concentration but higher light 
dosage, 4 and 6 min, did not survive, yet, 5 dpf embryos treated at these same 
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concentrations remained viable, but treatment induce tremors after 3 min of light 
exposure. The embryos were checked 24 h after the induction of tremors and all signs of 
this effect were absent. To further investigate, those same embryos were exposed to light 
again. This second exposure did not induce tremors or any other noticeable effects. When 
checked for cell death, these embryos exhibited enhanced cell death over controls. Based 
on these results we concluded that our targeted PDT agent effects specific cells, not all 
cells.  
Discussion 
 Folate is a B vitamin that plays a significant role in the prevention of neural tube 
defects (NTDs) and homocysteinemia (Barnabe, et al., 2015; Williams, et. al, 2015; 
Mills, et al., 1995; Rosenquist, et al., 1996). NTDs are malformations of the brain and 
spinal cord that occurs during gestation (Botto, et al., 1999; Lemuire, 1988).  Folate is 
needed for the methylation of homocysteine to form methionine and the synthesis of 
deoxynucleotides needed for DNA replication (Kang, et al., 1987; Krishnaswamy and 
Nair, 2001). Increased levels of homocysteine (homocysteinemia) are suspected to play 
important roles in developmental defects and is a risk factor for ischemic heart disease 
(Krishnaswamy and Nair, 2001; Wald, et al., 1998). NTDs and the effects of 
homocysteine have been documented in zebrafish (Blair, et al., 2005; Muralidharon, et 
al., 2015; Parkin, et al., 2006). These studies show that inhibition of enzymes that 
metabolize folate increased the occurrence of these conditions, and supplementation with 
folate decreased their occurrence.  
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 This study shows that cells that express the folate receptor can be selectively 
targeted and manipulated over cells that do not express the receptor.  Photodynamic 
treatment with 5 dpf resulted in the embryo remaining viable, yet tremors were induced. 
The results from the acridine orange assay demonstrates that we effected selected cells. 
This discovery can lead to further investigation of folate specific diseases and cancers, in 
addition to helping to understand embryonic development. 
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CHAPTER SIX 
CONCLUSIONS 
Photodynamic therapy (PDT) utilizes oxidative damage to kill cancerous cells.  
Light excites a photosensitizer (PS), which then reacts with oxygen to form a highly 
reactive oxygen species, which includes singlet oxygen.  This singlet oxygen reacts with 
cellular macromolecules to cause lethal damage. A prevalent concern with current FDA-
approved PDT drugs is that they exhibit low selectively for cancerous cells over healthy 
cells. An approach to enhance selectively is to covalently attach a targeting moiety to a 
PS. Many cancers overexpress the folate receptor (Zwicke 2012; Parker 2005), therefore 
generating an agent that selectively targets that receptor is beneficial. The main objective 
of this research was to synthesize and characterize the folate directed, protein based 
photodynamic therapy agent, FA-BSA-Ce6. In addition, we wanted to show its 
effectiveness as a selective cell targeting agent in cell culture and in vivo.  
The PS used in our conjugate was chlorin e6 (Ce6). Ce6 is a useful PS due to its 
absorbance in the optimum therapeutic window and high quantum yield of singlet 
oxygen. In addition, Ce6 has three carboxyl groups that provides sites for straightforward 
conjugation to other molecules that contain primary amines. A major drawback to Ce6 is 
its tendency to aggregate in aqueous environments. To overcome this disadvantage, we 
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conjugated Ce6 to the protein, bovine serum albumin (BSA) through an amidation 
reaction with the lysine residues on BSA.  
BSA served as a scaffold to which multiple molecules of Ce6 could be attached 
due to its high number of lysine residues. Although BSA has 60 lysine residues, Huang 
and Kim showed that only 34 of those residues could be modified via lysine specific 
crosslinkers and those lysines were between 20-24 Å apart. We hypothesize that due to 
steric hindrance we were able to attached 10 molecules of Ce6 and two molecules of FA 
onto one molecule of BSA despite using ratios of Ce6:BSA as high as 30:1 and FA:BSA 
as high as 10:1.  
An effective PDT agent will be phototoxic upon irradiation with light at the 
appropriate wavelength, but not cytotoxic in the absence of light. By using the singlet 
oxygen sensor, ρ-nitroso-N,N’-dimethylaniline (RNO), we were able to confirm that 
singlet oxygen was produced upon photoactivation of FA-BSA-Ce6 with 660 nm light 
and that singlet oxygen was not produce in the absence of light in vitro. In HeLa cell 
culture, cells that were exposed to FA-BSA-Ce6 varying in concentration from 1-10 µM 
that were kept in the dark resulted in 93% or greater cell survival. Cell survival decreased 
significantly, to as low as 5% upon photoactivation. In vivo studies with zebrafish 
embryos that were exposed to 5 and 10 µM FA-BSA-Ce6 but kept in the dark resulted in 
all embryos remaining viable for at least 48 h after exposure and none of the embryos 
remained viable after photoactivation with light times greater than 3 mins. Results from 
these in vitro and in vivo studies showed that FA-BSA-Ce6 is not cytotoxic in dark but it 
is phototoxic upon irradiation at 660 nm. 
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 As shown in Figure 12 HeLa cell survival is both concentration and light dose 
dependent. As the concentration of FA-BSA-Ce6 increase and as light exposure time 
increases (thus irradiation energy increases), cell survival decreases. The same effects are 
not seen with BSA-Ce6 (Figure 11). In fact, cell survival across all light irradiation times 
remained above 92% for BSA-Ce6. In zebrafish trials, the trend continued. Embryos 
exposed to BSA-Ce6 remained viable upon photoactivation. We synthesized a fluorescent 
analog of FA-BSA-Ce6 that contained FA-BSA, but Ce6 was replaced with Rhodamine B 
(RH), due to Ce6 poor fluorescence. Zebrafish embryos were treated with BSA-RH or FA-
BSA-RH. After allowing time for the embryo’s gut to empty, embryos treated with BSA-
RH showed little to no fluorescence. Embryos treated with the FA-BSA-RH brightly 
fluoresced. Additionally, the gene expression pattern for the folate receptor during 
zerbrafish early development was elucidated. Embryos treated with FA-BSA-RH exhibited 
fluorescence in the same pattern that was shown via whole mount in situ hybridization 
(WISH).  From the fluorescence data using FA-BSA-RH, the WISH data, the high cell 
survival after treatment with BSA-Ce6 and light, and the low cell survival from treatment 
with FA-BSA-Ce6 under the same conditions, it is highly suggestible that the conjugate is 
folate directed, and possibly being taken up via receptor mediated endocytosis.  
Photodynamic treatment using FA-BSA-Ce6 with embryos staged at 5 days post 
fertilization (dpf), induced tremoring, although the embryos remained viable. Acridine 
orange experiments showed that cell death was occurring after treatment, and many of 
those cells exhibited florescence with treatment with FA-BSA-RH, and those cells showed 
the presence of the folate receptor in WISH experiments. This shows that FA-BSA-Ce6 
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can selectively target cells that express the folate receptor. The synthesis of FA-BSA-Ce6 
coupled with being able to selectively target and effect folate dependent cells in zebrafish 
opens up many new opportunities for investigation. Zebrafish share a high homology 
similarity to humans therefore they are good candidates as in vivo models to look into folate 
specific diseases as well as cancers. The folate targeted PDT agent could also be used to 
aid in understanding embryonic development. Research has shown that folate may play a 
role in alzheimer’s disease, nueral tube defects, cancers, cardiac diseases, and other 
neurological conditions (Botez and Reynolds, 1979; Clarke, et al. 1998; Reynolds, 2002; 
Seshadri, 2001). By using a folate directed agent, these diseases can be further examined 
and understood.  
 Besides knowing that FA-BSA-Ce6 produces singlet oxygen and singlet oxygen is 
toxic to cells, the actual mode or pathway to cell death is not well understood. It is not clear 
at what point during irradiation is singlet oxygen being produce. The studies discussed in 
this dissertation were end point analysis studies. It would be beneficial for studies to be 
carried out that monitor the production of singlet oxygen. This can be accomplished by in 
assay ROS detectors. 
Depending on the stage of zebrafish embryo, results from photodynamic treatment 
varied. Younger staged embryos died, while older staged embryos survived but began to 
tremor. Studies that look into what particular cells are being effected in vivo can provide 
deeper insight. Investigations into an optimum conjugate exposure time, along with 
elucidating the cascading events that occur after treatment with FA-BSA-Ce6 can and 
should be further explored in both cell culture and in vivo. Those studies will provide 
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insight into how the cell responds to the treatment prior to cell death and can lead to more 
efficient and optimized conjugates.   
FA-BSA-Ce6 provided cell death in both HeLa cell culture and in zebrafish 
embryos. Available molecular oxygen is a big contributor to the effectiveness of PDT. 
Cancer tumors tend to be hypoxic. Therefore, if a PDT agent is able to not only selectively 
target the cancerous cell, but also bring with it molecular oxygen, the effects of the PDT 
agent can be increased. Research in our laboratory has shown that a nanoparticle of up to 
8 modified hemoglobin molecules can be synthesized, and this nanoparticle has a high 
affinity for oxygen (Webster, 2016 in press). Therefore, synthesizing an analog of FA-
BSA-Ce6, by replacing BSA with the modified hemoglobin, can potentially deliver up to 
10 molecules of Ce6, along with 8 molecules of hemoglobin can be beneficial. Each 
molecule of hemoglobin will potentially carry a molecule of oxygen inside the tumor, 
thereby increasing the availability of molecular oxygen, thus increasing the generation of 
singlet oxygen.   
FA-BSA-RH was able to selectively target cells that express the folate receptor. 
Therefore, this analog can potentially be used for tumor imaging before and/or after 
treatment. Many cancers are treated from multiple approaches. Being able to have the 
tumor fluoresce can optimize surgical removal of tumors. In addition, provide a way to 
visualize how much of the tumor remains after surgery or after other cancer related 
treatments.    
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APPENDIX A 
HEMOGLOBIN BASED PDT AGENTS 
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PDT potency has a direct relationship with oxygen availability. Cancerous cells 
are typically hypoxic due to the aggregation of cells, which prevents an appropriate 
vascular system from being developed. Hence, the more oxygen available to the 
photosensitizer the more cellular damage can be done. Crosslinked hemoglobin (XLHb) 
has been shown to have an increased oxygen affinity. Therefore, conjugating Ce6 to 
XLHb should allow for more molecular oxygen to be present inside the targeted cells, 
and result in increased cellular death.   
We successfully synthesized 60 µM XLHb, FA-XLHb, and FA-XLHb-Ce6. The 
conjugates were extracted using cold acid/acetone mixture to quantify the amount of folates 
and chlorin e6 molecules covalently bound to the protein as described in Chapter Three. 
Under these harsh conditions, the heme dissociates from the globin, and the globin 
precipitates along with any covalently bound molecules. FA-XLHb-Ce6 proved to have 
approximately 2.67 folates and 3 chlorin e6 molecules bound per protein molecule (Table 
4). 
 
 
. 
 
Table 4. Acid/Acetone Extraction. Average of 2.67 folates, and 3 chlorin e6 molecules 
bounds per XLHb molecule 
 
Trials # of FA # of Ce6  
1  3 3 
2 2 3 
3 3 3 
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 A key component to successful PDT is providing sufficient oxygen that can be 
converted into singlet oxygen. The FA-XLHb-Ce6 conjugate was assayed for its oxygen 
affinity. An oxygen binding curve was collected (Figure 21) and a Hill plot was constructed 
to determine the conjugate’s p50 (Figure 22). The p50 is the pO2 at which the hemoglobin 
becomes 50% saturated with oxygen. As the p50 decreases, oxygen affinity increases. 
Unmodified hemoglobin has a p50 of approximately 26.5 mmHg. The p50 for the 
crosslinked hemoglobin that was used to synthesize FA-XLHb-Ce6 was determined to be 
10.72 mmHg (+/- .245). The p50 for FA-XLHb-Ce6 was determined to be 7.98 mmHg (+/- 
.215) (Figure 21 and Table 5).  
 From Hill plots a Hill coefficient, “n”, can be calculated. The Hill coefficient is a 
measure of cooperativity. Cooperativity is a measure of affinity for a ligand, and in our 
case an oxygen molecule, to bind to a substrate (crosslinked hemoglobin) upon the binding 
of another ligand at a different binding site. A Hill coefficient that is greater than one 
denotes positive cooperativity. The Hill coefficient for XLHb was determined to be 1.03 
(+/- .010) and for FA-XLHb-Ce6 it was determined to be 1.70 (+/- .682) (Table 5 and 
Figure 22). This data demonstrates that upon conjugating XLHb to folate and chlorin e6 its 
oxygen affinity was enhanced. These results indicated that FA-XLHb-Ce6 oxygen affinity 
is greater than myoglobin (2.5 mmHg), yet lesser than Hb. Therefore, FA-XLHb-Ce6 
should be able to hold on to oxygen in normoxic conditions, and deliver its oxygen in 
hypoxic conditions, such as in cancerous tumors. 
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Sample P50 n 
XLHb 10.72 (+/- .245) 1.03 (+/- .010) 
FA-XLHb-Ce6 7.98 (+/- .215) 1.70 (+/- .682) 
Table 5. P50 and Hill Coefficients. Data table of calculated p50 and hill coefficient for 
XLHb abd FA-XLHb-Ce6 
 
 
Figure 21. Oxygen Binding Curves for FA-XLHb-Ce6. 
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Figure 22. Hill Plots Calculated from Oxygen Binding Curves 
             Each conjugate was subsequently assayed for phototoxicity and dark cytotoxicity 
in HeLa cell culture using a 96 well plate and Cell Titer Blue Assay as previously 
described in Chapter Three.  
 
Figure 23. XLHb Based Conjugates Cell Culture Results. 
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The crosslinked hemoglobin compounds were shown to be cytotoxic. Crosslinked 
hemoglobin provided 118.22% cell survival, while the XLHb-Ce6 and FA-XLHb-Ce6 
provided 63.57% and 50.69% cell survival, respectively. Phototoxicity results were 
81.13%, 18.52%, and 58.32% for XLHb, XLHb-Ce6, FA-XL-Ce6 respectively (Figure 
23). These results do not support our hypotheses. After further examination of the 
hemoglobin based conjugates, we determined that the hemoglobin had oxidized to 
become methemoglobin. Methemoglobin contains Fe3+. This oxidized form of 
hemoglobin has a lower capacity to bind oxygen in comparison to unoxidized 
hemoglobin. Conversely, Fe3+  has a higher affinity for bound oxygen. When oxygen 
binds to methemoglobin the remaining Fe2+ of the tetramer have an increased affinity of 
oxygen. This results in the methemoglobin poorly delivering oxygen to tissues, causing 
hypoxia, which is lethal to cells.   The samples were placed onto a dithionite reduction 
column, and results were not improved. The conjugates were successfully reduced, but 
after 24 h of incubation in a humidified atmosphere we hypothesize that the conjugates 
returned to the met-form. 
The results obtained using a significant lesser amount of conjugates (10 µM) of 
BSA based conjugates provided more consistent (based on standard deviations) data and 
proved to be a more effective conjugate. It should be noted that the amount of light 
energy used was in these XLHb studies was 81 mJ/cm2/nm while the BSA studies were 
carried out with 168 J/cm2/nm.  
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Brief Methods 
 Synthesis of XLHb. Prior to crosslinking hemoglobin at the β82-Lys residues, 
HbA was dialyzed in MOPS buffer at pH 7.0. The HbA was then reacted with bis-(3,5 
dibromosalicyl) fumarate (DBSF) at a 1:1.1 molar ratio. Subsequently, it was incubated 
for 2h at 37 °C. The reaction was terminated on ice and reaction mixutre was dialyzed in 
.01 M Tris buffer at pH 8.5 overnight. The crosslinked hemoglobin was separated from 
umodified hemoglobin using a Sephadex A-50 column with a pH gradient of 8.5-7.0. 
XLHb was confirmed by SDS PAGE-gel electrophroesis.  
Synthesis of FA-XLHb. Folic acid was placed inside of a small eppendorf tube 
covered with foil and dissolved in 200-300μl of dry DMSO. Next, it was incubated with a 
10 fold molar excess of 1-ethyl-3-(3-dimehtylaminopropyl) carbodimide(EDC) and a 20 
fold molar excess of N-hydroxysuccinimide (NHS) at room temperature for 30min. A 10 
fold molar excess of the esterified “acitivated” folic acid per XLHb tetramer was added to 
the XLHb solution that was previously dialyzed in bicarbonate buffer at pH 8.0 The 
mixture was incubated for 24h at room temperature and quenched with ethanolamine. 
The excess folic acid, NHS and ethanolamine was removed by dialyzing overnight in 
PBS at pH 7.4.If the FA-XLHb were to be added to chlorin e6 it was dialyzed in 
bicarbonate buffer at pH 8.0. 
Synthesis of XLHb-Ce6. Chlorin e6 was placed inside of a small eppendorf tube 
and covered with foil and dissolved in 200-300μl of dry DMSO. Next, it was incubated 
with a 10 fold molar excess of 1-ethyl-3-(3-dimehtylaminopropyl) carbodimide(EDC) 
and a 20 fold molar excess of N-hydroxysuccinimide at room temperature for 30min. A 
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10 fold molar excess of the esterified “acitivated” chlorin e6 per XLHb tetramer was 
added to XLHb that was previously dialyzed in bicarbonate buffer at pH 8.0 The mixture 
was incubated for 24h at room temperature and quenched with ethanolamine. The excess 
chlorin e6, NHS and ethanolamine was removed by dialyzing overnight in PBS at pH 7.4.  
Synthesis of FA-XLHb-Ce6. Chlorin e6 was placed inside of a small eppendorf 
tube and covered with foil and dissolved in 200-300μl of dry DMSO. Next, it was 
incubated with a 10 fold molar excess of 1-ethyl-3-(3-dimehtylaminopropyl) carbodimide 
(EDC) and a 20 fold molar excess of N-hydroxysuccinimide (NHS) at room temperature 
for 30min. A 10 fold molar excess of the esterified “acitivated” chlorin e6 per XLHb 
tetramer was added to the FA-XLHb solution that was previously dialyzed in bicarbonate 
buffer at pH 8.0 The mixture was incubated for 24h at room temperature and quenched 
with ethanolamine. The excess chlorin e6, NHS and ethanolamine was removed by 
dialyzing overnight in PBS at ph 7.4.  
Oxygen binding. Four milliliters XLHb or FA-XLHb-Ce6 in MOPS buffer pH 
7.0 was placed inside of the Hemox Analayzer Model B. The sample was allowed to 
equilibrate until it has reached 37°C (approximately 30min). The XLHb is oxygenated 
with air supplied from an air tank. After the XLHb has been completely oxygenated and 
the pO2 has been adjusted to 150mmHg, the sample is deoxygenated by switching off the 
air and turning on the nitrogen. The completion of the curve is reached when the pO2 
approaches zero.  
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A PEG based conjugate was synthesized in addition to the protein based 
conjugates. The amines on the PEG allowed for the same carbodiimide esterification 
chemistry to be used for conjugation of folate and dye that was used with the protein 
based conjugates. It also helped maintain solubility. The 4 arm-amine PEG 
(CreativePEGworks, Winston Salem, NC 27113) (Figure 24), was placed inside of a vial 
covered with foil. A fifty fold molar excess of chlorin e6, 50 fold molar excess of 1-
hydroxybenzotriazole, 17 fold molar excess of folic acid, 50 fold molar excess of EDC 
was added to the vial and they were dissolved with 3-5mL of dry DMF. Once all reagents 
were dissolved a 50 fold molar excess of triethylamine was addition to the mixture and 
the vial was placed on a stir plate at  4°C. The resulting mixture was separated using gel 
filtration, and the number of molecules bound was determined via UV-Vis 
spectrophotometry for each fraction collected. Chlorin e6 has maxima absorption at 660 
nm, and folate has maxima absorption at 363 nm. The absorbances at 363 nm was 
corrected for slight overlapping absorption of chlorin e6 and the ratio of dye to folate was 
calculated (Table 6). It was determined that fraction two contained the desired the ratio, 
3:1, and was subsequently used in two HeLa Cell Culture trials. The results of the two 
trials indicated that the 19% and 48% of cells survived respectively after irradiation with 
light. In the dark the conjugates showed 54% cell survival. Therefore, the conjugate was 
deemed cytotoxic. It should be noted that the unlike the protein based conjugates cell 
survival was assayed using MTT and not Cell Titer Blue.  
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Figure 24. 4-Arm Amine PEG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Ratio of Ce6:FA Bound to 4-Arm Amine PEG. Fraction separated and collected 
via gel filtration using a G-10 Sephadex column. An UV-vis spectrum was taken of each 
fraction and subsequently ratios were determined 
 
 
 
Fraction Ratio (Ce6:FA) 
1 7.88 
2 3.09 
3 3.89 
4 3.36 
5 2.56 
6 4.28 
7 4.74 
8 3.96 
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LAMP STUDIES 
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  To determine the exact energy output of the lamp, its energy was measured 
against a calibrated light source. These experiments were carried out with the assistance 
of Dr. Robert Polak in the Physics Department at Loyola University Chicago. The 
experiment was briefly explained by Dr. Polak in an email sent to RoJenia Jones on 
August 12, 2014. The text from the email is below: 
“The total power emitted in electromagnetic waves for a light source is called the radiant 
flux and is measured in units of Watts (W).  The power emitted by the light source for an 
electromagnetic wave at a specific wavelength is called spectral radiant flux and is 
typically measured in (W/nm).  
To determine the spectral radiant flux of an object, we compare the light being emitted by 
it at a specific wavelength to that being generated by a calibrated light source.  In this 
case, we have a calibrated light from Labsphere, which consists of a 2π (“two-pi”) 
incandescent light source being driven by a calibrated power supply.  This light enters an 
integrating sphere and the detector used is an opal glass.  By comparing the light energy 
on the detector to that of an unknown source at a specific wavelength, we can then 
determine the spectral radiant flux of the unknown source. 
The opal glass itself is not a detector though.  Instead we use a Topcon SR-3 
Photoradiometer to determine the spectral radiance (light energy per unit area per unit 
solid angle) on the surface of the opal glass.  The spectral radiant flux of the unknown 
source can then be determined by: 
 the spectral radiant flux of the unknown source, is the spectral radiant flux of the 
calibrated light source (data provided by Labview), is the spectral radiance of the opal 
glass with the unknown source and is the spectral radiance of the opal glass with the 
calibrated light source. 
In this case, we actually aren’t interested in the spectral radiant flux of the unknown light 
source, but the light power per unit area per unit wavelength where the cultures are 
placed.  This is the spectral irradiance and is simply the spectral radiant flux of the light 
entering the integrating sphere through an open port divided by the area of that port. 
To determine this, the light source was placed 3 inches from the port opening and moved 
to measure the light entering the sphere that would correspond to different positions of 
the culture.  We broke this into 12 different bins (each representing a different area of the 
culture tray).  Using the above formula to determine the spectral radiant flux incident 
upon each bin, we can then determine the spectral irradiance by dividing this result by the 
area of the port opening” 
 
All measurements were taken with the source 16 inches from the tray.  The 
irradiance will go as 1/r2 from the source, so changing the distance from 16 inches to 18 
90 
 
inches will result in a 21% decrease in the irradiance. There were three trials completed 
for each lamp source tested. Below is a diagram of each “bin”: 
 
1 2 3 
4 5 6 
7 8 9 
10 11 12 
 
Figure 25. Lamp Bins 
 
All data reported in this dissertation (unless otherwise stated) was carried out with a 120 
red LED lamp (660 nm) purchased from Elixa (http://www.elixa.com/shop/120-led-red-
660nm/). The LED array is approximately 3/4″x 2″x 4″.  The results from the light 
intensity study for wavelengths 380 – 780 nm is presented in Figure 26. 
 
In Table 7 and Figure 27, the data is presented for the amount of energy produced at 660 
nm with the lamp 3 inches away from the test surface for 1-10 min. 
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Figure 26. Lamp Intensity 
 
 
 
MINUTES J/CM2/NM 
1 5.619322266 
2 11.23864453 
3 16.8579668 
4 22.47728906 
5 28.09661133 
6 33.7159336 
7 39.33525586 
8 44.95457813 
9 50.5739004 
10 56.19322266 
 
Table 7. Energy Output at 660 nm for 1-10 minutes 
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Figure 27. Energy output at 660 nm for 1-10 minutes 
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